**M. RITA I. YOUNG, Ph.D.**

Associate Chief of Staff for Research & Development (151)

Ralph H. Johnson VA Medical Center

109 Bee Street, Charleston, SC 29401

Phone: (843) 789-6707

e-mail: rita.young@med.va.gov

Professor of Otolaryngology and Professor of Medicine

Medical University of South Carolina, SC 29425

**EDUCATION**:

B.S. - 1973 Department of Biology/Physics

S.U.N.Y. at Stony Brook, Stony Brook, NY

M.S. - 1974 Department of Veterinary Medicine

University of Idaho, Moscow

Ph.D. - 1978 Department of Bacteriology and Public Health

Washington State University, Pullman, WA

**RESEARCH AND PROFESSIONAL EXPERIENCE**:

1975-1978 Teaching Assistant, Department of Bacteriology

Washington State University, Pullman, WA 99163

1978-1980 Post-Doctoral Fellow, Immunobiology Research Center

University of Wisconsin, Madison, WI 53706

1980-1983 Assistant Professor

Indiana University Center for Medical Education at Muncie

Ball State University, Muncie, IN 47306

1983-1986 Associate Professor

Indiana University Center for Medical Education at Muncie

Ball State University, Muncie, IN 47306

1985-1986 Visiting Research Scientist, Pathology Research

Hines VA Hospital, Hines, IL 60141

1986-1989 Research Health Scientist, Pathology Research

Hines VA Hospital, Hines, IL 60141

1986-1993 Associate Professor, Department of Pathology

Loyola University Stritch School of Medicine, Maywood, IL 60153

1989-1998 Research Career Scientist

Hines VA Hospital, Hines, IL 60141

1993-2003 Professor of Pathology

Loyola University Stritch School of Medicine, Maywood, IL 60153

1994-2003 Professor of Otolaryngology and Director of Otolaryngology
Research

Loyola University Stritch School of Medicine, Maywood, IL 60153

1995-2003 Full Member of the Graduate Faculty

Loyola University Stritch School of Medicine, Maywood, IL 60153

1999-2003 Senior Research Career Scientist

Hines VA Hospital, Hines, IL 60141

1998-2003 Associate Chief of Staff for Research

Hines VA Hospital, Hines, IL 60141

2003-present Associate Chief of Staff for Research & Development

Ralph H. Johnson VA Medical Center, Charles, SC 29401

2003-present Senior Research Career Scientist

Ralph H. Johnson VA Medical Center, Charleston, SC 29401

2003-2007 Professor of Medicine and of Otolaryngology

Medical University of South Carolina, Charleston, SC 29425

2007-present Professor of Otolaryngology and of Medicine

Medical University of South Carolina, Charleston, SC 29425

**RESEARCH SUPPORT:**

**PAST FUNDING (P.I. is M. Rita I. Young, unless indicated):**

1\. Delaware County Cancer Society, Inc., Muncie, Indiana.

Stimulation of tumor rejection by anti-PGE~2~ antibodies.

January 1981 - December 1981. \$1,720.

2\. Elsa U. Pardee Foundation, Midland, Michigan.

Tumor detection by monitoring serum prostaglandin E~2~ concentrations.

January 1982 - December 1982. \$17,684.

3\. Delaware County Cancer Society, Inc., Muncie, Indiana.

Prevention of tumor metastasis with monoclonal anti-prostaglandin E~2~
antibodies.

June 1982 - November 1983. \$8,895.

4\. American Lung Association, New York, New York.

Controlling lung malignancies with indomethacin.

July 1983 - June 1984. \$13,953.

5\. Delaware County Cancer Society, Inc., Muncie, Indiana.

Monitoring tumor development by quantitating serum prostaglandin E~2~
Levels.

January 1984 - June 1985. \$19,067.

6\. American Lung Association of Indiana, Indianapolis, Indiana.

Alveolar macrophage-mediated immunosuppression in mice bearing Lewis
lung carcinoma.

July 1985 - June 1986. \$8,943.

7\. Public Health Service, Bethesda, Maryland. (CA45080)

Prostaglandin E~2~ promotes tumor dissemination.

September 1985 - April 1988. \$115,706.

8\. Public Health Service, Bethesda, Maryland.

Tumor-induced suppression of alveolar macrophages.

January 1986 - December 1987. \$47,653.

9\. Medical Research Service, Veterans Administration, Washington D.C.

The *in vitro* activation of macrophage suppressor cells.

Co-Investigator: H. Terry Wepsic, M.D., 10% effort

April 1986 - March 1987. \$49,470.

10\. Oncology Center Grant, Loyola University Medical Center, Maywood,
Illinois

Prostaglandin E~2~ promotes tumor dissemination.

October 1987 - April 1988. \$18,925.

11\. Medical Research Service, Veterans Administration, Washington D.C.

Hematopoiesis and bone marrow suppressor cells in tumor bearers.

Co-Investigator: H. Terry Wepsic, M.D., 10% effort

April 1987 - March 1990. \$329,300.

12\. Greenwich Pharmaceuticals, Ft. Washington, Pennsylvania.

Mechanisms of action of anti-inflammatory compounds.

May 1987 - Dec. 1992. \$244,000.

13\. Public Health Service, Bethesda, Maryland.

Prostaglandin E~2~ promotes tumor dissemination.

April 1988 - March 1992. Direct costs: \$190,544.

14\. LyphoMed, Inc., Melrose Park, IL

Effects of experimental compounds on macrophage secretion of TNF.

Aug. 1991 - Jan. 1992. \$4,100 (contractual studies).

15\. American Cancer Society, Illinois Division, Chicago, Illinois.

Stimulation of the metastatic properties of tumor cells GM-CSF.

August 1992 - January 1994. \$34,960

16\. Public Health Service, Bethesda, Maryland.

Myeloid differentiation therapy reduces suppressor cells.

July 1990 - June 1994. Direct costs: \$230,380.

17\. Medical Research Service, Veterans Administration, Washington, D.C.

Stimulation of immune suppressor cells by myelopoiesis-inducing tumors.

Oct. 1990 - March 1994. \$173,646.

18\. The Alzheimer Foundation, Chicago, Illinois

Microglial activation when regulation by prostaglandin E~2~ becomes
defective.

December 1994 - March 1996. Direct costs: \$30,000.

19\. Public Health Service, Bethesda, Maryland: RO1-CA45080

Prostaglandin E~2~ promotes tumor dissemination.

July 1992 - April 1997. \$494,500.

20\. Medical Research Service, Department of Veterans Affairs,
Washington, D.C.

Therapy to block lung cancer induction of immune suppressor cells.

April 1994 - March 1997. \$230,000

22\. Adrian Labs / Pharmacia Inc.

Analyses for TNF-α.

November 1992 -- November 1998. \$11,500 (contractual studies).

23\. American Cancer Society, Atlanta, GA.

Angiogenic factors produced by human head and neck cancers.

July 1995 - June 1998. \$90,000

Career Development Award - Dr. Guy J. Petruzzelli, Dept. Otolaryngology,
Loyola Univ.

Sponsor/Mentor: Dr. M. Rita I. Young

24\. Public Health Service, Bethesda, Maryland: RO1-CA48080

Myeloid differentiation therapy to enhance immune stimulatory therapy.

January 1995 - December 1998. \$366,269.

25\. Procter & Gamble University Exploratory Research Program

The role of microglia in Alzheimer's disease.

M. Prechel is PI, with M.R.I. Young as Co-Principal Investigator

July 1996 - June 1999. \$150,000.

26\. Theodore & Vada Stanley Foundation

Serotonergic-mechanisms of immune function in Schizophrenia and
affective disorders.

J. Kut is PI, with M.R.I. Young as co-Principal Investigator

October 1997 - September 1999. \$99,320.

27\. Public Health Service, Bethesda, Maryland. R55 CA78262.

Dendritic cell growth from suppressor cells of cancer patients

August 1998 -- September 2000 \$80,000 (pilot study)

28\. Medical Research Service, Department of Veterans Affairs,
Washington, D.C.

Therapy to enhance anti-cancer immune reactivity.

April 1997 - March 31, 2002 \$505,200.

29\. Public Health Service, Bethesda, Maryland. R21-CA77208-1.

Vitamin D~3~ to reduce suppressor cells in cancer patients.

April 1998 -- March 2001 \$161,145

30\. Public Health Service, Bethesda, Maryland. RO1 GM56424.

Mechanism of myeloid maturation arrest in burn sepsis

R. Shankar is PI, with M.R.I. Young as co-Investigator

May 1998 -- April 2001 \$371,623.

31\. Department of Veterans Affairs, Washington, D.C. -- REAP
application

Promotion of functional recovery following spinal cord injury.

K. Jones and T Khan are PIs, with M.R.I. Young as co-Investigator.

October 1998 -- September 2001; \$225,500, M.R.I. Young; \$1,350,000
total.

32\. American Cancer Society, Illinois Division, Ind. #00-42

Tumor-induced immune inhibitory CD34^+^ cells resist apoptosis.

R. Wrone-Smith is PI, with M.R.I. Young as co-Investigator.

August 2000 -- July 2001 \$49,516.

33\. Public Health Service, Bethesda, Maryland. RO1-CA45080-10.

Protein phosphatases-1 and -2A restrict tumor metastasis.

May 1997 - April 2003 \$893,549.

34\. Public Health Service, Bethesda, Maryland. R01 CA79768.

Phosphatase regulation of tumor-induced angiogenesis.

March 1999 -- February 2003 \$475,939.

35\. Kenwood Laboratories, Inc., Chicago, IL.

Intracellular activities of anti-inflammatory experimental
carbohydrates.

June 1990 -- June 2003. \$70,000 (contractual studies).

36\. Aventis Pharmaceuticals, Inc.

Combination docetaxel plus vitamin D~3~ as an immune therapy in animals
bearing head and neck squamous cell carcinomas.

January 2004 -- December 2005 \$50,000

37\. Medical Research Service, Department of Veterans Affairs,
Washington, D.C.

*In situ*-activated immunotherapy to block post-surgical cancer
recurrence

April 2002 -- March 2006; \$554,500

38\. Public Health Service, Bethesda, Maryland. 1RO1 CA85266

Contribution of vasculogenesis to tumor vascularization.

May 1, 2000 -- April 30, 2005 (- April 30, 2007 no cost extension)
\$810,000 direct costs.

39\. CTSA Institutional Pilot Project Program

Immunotherapy to prevent oral premalignant lesion recurrence and oral
cancer

February 16, 2007 -- February 15, 2008 \$50,000

**CURRENT FUNDING SUPPORT (P.I. is M. Rita I. Young):**

1\. Public Health Service, Bethesda, Maryland. RO1 CA97813.

Blocking angiogenesis by targeting PP‑2A pathways.

April 2003 -- March 2008; April 2008 -- March 2009, no cost extension
\$1,023,500

2\. Clinical Sciences Research Service, Department of Veterans Affairs,
Washington, D.C.

Vitamin D therapy to enhance intratumoral anti-cancer immune reactivity

October 2004 -- September 2009 \$747,000

3\. Research Service, Department of Veterans Affairs, Washington, D.C.

Defining and interrupting the pathways that lead to HNSCC invasiveness.

October 2007 -- September 2011 \$507,000

4\. Public Health Service, Bethesda, Maryland.

Macrophage-driven progression of premalignant oral lesions toward
invasiveness.

August 2008 -- June 2012 \$1,000,000

**PENDING FUNDING SUPPORT (P.I. is M. Rita I. Young):**

1\. Public Health Service, Bethesda, Maryland.

Immunotherapy to prevent oral premalignant lesion recurrence and oral
cancer.

Fundable score -- awaiting verification of funding amount and durations

2**.** Clinical Sciences Research Service, Department of Veterans
Affairs, Washington, D.C.

Vitamin D plus celecoxib therapy to stimulate intratumoral immune
reactivity.

Submitted September 2008

**ADMINISTRATION & SERVICE:**

**PRIOR ADMINISTRATIVE ACTIVITIES:**

1998 -- 2000 Associate Chief of Staff for Research, Edward Hines, Jr. VA
Hospital and North Chicago VA Medical Center (responsible for
development, oversight, compliance, fiscal management, and
representation of research programs of 2 major VA Hospitals in Chicago
area)

1998-2003 President of the Chicago Association for Research and
Education in Science (VA-affiliated non-profit corporation)

1995-2003 Director, Research Program for the Department of
Otolaryngology, Loyola University Stritch School of Medicine

1992 -- 2002 Organizer and Coordinator, Annual Research Symposium
including Hines VA Hospital, North Chicago VA Medical Center, Loyola
University Stritch School of Medicine, Fitch School of Medicine, and the
Great Lakes Naval Dental and Medical Research Institute.

1998-2003 Chair of VISN12 Research Council (composed of directors of VA
research programs at Hines, North Chicago, Chicago, Milwaukee and
Madison

> **CURRENT ADMINISTRATIVE ACTIVITIES:**

2003-present Associate Chief of Staff for Research, Ralph H. Johnson VA
Medical Center (responsible for development, oversight, compliance,
fiscal management, and representation of research program of Charleston
VA Hospital)

2003-present Chairman of the Board of Directors of the Charleston
Research Institute (VA-affiliated non-profit corporation)

2004-present Chair, VA VISN 07 Research Council (composed of directors
of VA research programs at Charleston, Columbia, Augusta, Atlanta,
Birmingham and Tuscaloosa

> **SIGNIFICANT NATIONAL BOARD ACTIVITIES:**

2005 Member of the Search Committee for the Director of Operations, VA
Office of Research and Development, Washington, D.C.)

2005 Member of the Search Committee for the Director of Clinical
Sciences Research Program, VA Office of Research and Development,
Washington, D.C.)

2002-2005 Board of Directors Member, National Association of VA Research

& 2005-2008 and Education Foundations (parent organization of
VA-affiliated non‑profit corporations)

2004-2008 Field Research Advisory Council (one of 9 advisors to the VA
Office of Research and Development, Washington, D.C.)

2006-present External Advisory Board for SPORE in Head and Neck Cancer,
University of Michigan, Ann Arbor

2007-present Advisory Board for Department of Defense application
W91ZSQ6289N610: Development of Augmented Leukemia/Lymphoma Specific
T‑cell Immunotherapy for Deployment with Haploidentical Hematopoietic
Progenitor-Cell Trasplant. P.I.: Lawrence Cooper; M.D. Anderson

> **LOCAL COMMITTEE ACTIVITIES:**
>
> **Hines VA Hospital, Hines, IL**

1986-2003 Science Student Award Selection Panel; Member/Mentor

1988-2003 Basic Scientist Position Review Panel

1989-1997 Research Radiation Safety Officer

1990-1993 Research Steering Committee

1990-1993 Hines VA Hospital Study Group on Aging

1990-1995 Research Safety Committee

1990-1997 Hospital Radiation Safety Committee

1991-1997 New Research Employee Orientation Panel

1991-2003 Hospital Research & Development Committee

1992-1998 Advisory Board for Biological Psychiatry Section

1996-1998 Chair, Research & Development Committee, Hines VA Hospital

1998-1999 Quality Improvement Team

1998-2003 Medical Executive Committee

1998-2003 Dean's Committee

1999--2000 Chair, Executive Council of the Clinical Staff

2000-2003 Executive Council of the Clinical Staff

1999-2003 Hines Leadership Council

> **Loyola University Stritch School of Medicine, Maywood, IL**

1994-1997 Neurosciences and Aging Institute Research Grant Review
Committee

1998-2001 Member of the Committee on Medical Student Admissions

1992-2002 Research Funding Committee

1999-2003 Member of the Internal Advisory Council of the Cardinal
Bernardin Cancer Center

> **Ralph H. Johnson VA Medical Center, Charleston, SC**

2003-2005 VA Clinical Executive Board

2003-2005 VA Resource Allocation Board

2004-2005 Strategic Planning Council

2003-present VA VISN 07 Research Council

2003-present Research and Development Committee

2003-present VA Academic Partnership Council

2003-present Institutional Animal Care and Use Committee

2003-present Biosafety Committee

2004-present Internal Advisory Board of the Targeted Research
Enhancement Program (Health Service Research & Development Program)

> **Medical University of South Carolina**

2003-present Executive Research Council

2003-present Associate Deans for Research Council

2005-2007 Faculty Senate

2005-2007 Governance Committee of the Faculty Senate

2006-2007 Co-Leader of Research Administration CTSA Work Group

2007-2009 Faculty Senate

2007-2009 Executive Committee of the Faculty Senate

**REVIEWER OF GRANT PROPOSALS**:

1990, 1992 Illinois Cancer Council, Chicago, IL

1990-1994 Research Advisory Group (RAG B), Department of Veterans
Affairs Central Office, Washington, D.C.

1993-1996 VA Merit-Review Board for Immunology

1995-1997 Experimental Therapeutics-2 Study Section, National Institutes
of Health, ad-hoc

1997-2001 Experimental Therapeutics-2 Study Section, National Institutes
of Health, full member

1997 National Institutes of Health PO1 site visit team member

1990-present Ad hoc reviewer for Department of Veterans Affairs

1993, 1996 National Aeronautics and Space Administration, American
Institute of Biological Sciences, Washington, D.C.

1997-2001 US Army Medical Research and Materiel Command: Breast and
Prostate Cancer Research Initiatives; Clinical and Experimental
Therapeutics Study Sections

1998-2002 Department of Veterans Affairs Merit Review Medical Advisory
Board

1998-2003 Department of Veterans Affairs Review Committee for
Historically Black Colleges and Universities

2002-2005 Department of Veterans Affairs Oncology Merit Review Board

2003 Experimental Therapeutics-2 Study Section, National Institutes of
Health

2003-2005 Cancer Immunology Immunopathology Study Section, National
Institutes of Health.

2004 Department of Veterans Affairs Review Board for Clinical Research
Centers of Excellence

> **EDITORIAL BOARD MEMBERSHIPS:**

1998-2003 Editorial Board for Cancer Immunology and Immunotherapy

1998-2003 Editorial Board of Investigative Urology

2002-present Editorial Review Panel for Otolaryngology -- Head and Neck
Surgery

2003-2008 Editorial Board for Cancer Immunology and Immunotherapy

2008-2010

> **JOURNAL REVIEWER (representative listing)**:

1.  International Journal of Cancer

2.  British Journal of Cancer

3.  Cancer Research

4.  Invasion and Metastasis

5.  Journal of Immunology

6.  Cancer Research

7.  Journal of Leukocyte Biology

8.  Laboratory Investigation

9.  Archives of Pathology & Laboratory Medicine

> **CURRENT MEMBERSHIPS IN PROFESSIONAL AND HONORARY SOCIETIES**:

1\. American Association of Immunologists

2\. American Association for Cancer Research

3\. Reticuloendothelial / Leukocyte Biology Society

4\. American Association for the Advancement of Science

5\. Women in Cancer Research

**HONORS AND AWARDS**:

1978, 1979 National Institutes of Health Research Service Award

1989 Japan Fellowship for Foreign Investigators

1989-1994 Associate Research Career Scientist Award, Department of
Veterans

& 1994-1998 Affairs, Washington, D.C.

1998 Research Career Scientist Award, Department of Veterans Affairs,
Washington, D.C.

1999-2006 Senior Research Career Scientist Award, Department of Veterans
Affairs, Washington, D.C.

2005 Federal Employee of the Year Award (Charleston Region)

2006-2013 Senior Research Career Scientist Award, Department of Veterans
Affairs, Washington, D.C.

**TEACHING:**

**PAST FORMAL CLASSROOM TEACHING RESPONSIBILITIES (1980-1985)**:

1.  Medical Microbiology: Medical Immunology and Medical Virology;
    Indiana University Center for Medical Education, Course taught each
    winter quarter during 1980-1985 to first year medical students.

2.  General Immunology: (Bio 344) Undergraduate course taught each fall
    and spring quarter during 1980-1984 to Ball State University
    students majoring in Medical Technology.

3.  Immunology: (Bio 544) Graduate immunology course taught each fall
    and spring quarter during 1980-1984 at Ball State University,
    Biology Department.

4.  General Virology: (Bio 331) Undergraduate course taught each fall
    quarter during 1980-1983 at Ball State University, Biology
    Department.

5.  Virology: (Bio 531) Graduate course taught each fall quarter during
    1980-1983 at Ball State University, Biology Department.

**PAST STUDENT MENTORSHIP:**

**Thesis Advisor for Graduate Students at Ball State University**

1.  Jill A. Simmermaker: Prostaglandin E~2~ regulates production of
    tumoristatic factors by macrophage like P388D1 cells. M.S., 1984.

2.  Clayton E. Estep: The effect of indomethacin on the macrophage
    tumoristatic activity of tumor-bearing mice. M.S., 1984.

3.  Cathy S. Hoover: The effects of tumor-derived prostaglandin E~2~ on
    the tumoricidal activities of cytotoxic T lymphocytes. M.S., 1984.

4.  Piruz Nahreini: Regulation of Lewis lung carcinoma cell growth by
    prostaglandins. M.S., 1984.

5.  Elizabeth H. Wheeler: Natural killer cell activity in mice bearing
    Lewis lung carcinoma. M.S., 1985.

6.  Roger A. Endicott: Immunoregulation of T-lymphocyte proliferative
    activity by alveolar macrophages from mice bearing Lewis lung
    carcinoma tumors. M.S., 1986.

7.  Michael P. Mahan: The effects of vigorous physical exercise on the
    immune system. Ed.D., 1987.

8.  Patrick Duffie: The functional assessment of pulmonary alveolar
    macrophages in mice bearing Lewis lung carcinoma. Ed.D., 1988.

**Thesis Advisor for Graduate Students at Loyola University**

1.  Advisor for doctoral candidates: Department of Cell Biology,
    Neurobiology and Anatomy\
    Jodi Jackson, Ph.D. awarded 2002\
    Lisa Shafer, Ph.D. awarded 2002

2.  Member of graduate committees in the Department of Microbiology:\
    Clive Landis, Ph.D. awarded 1989\
    David Beno, Ph.D. awarded 1990\
    Silvia Kiertscher, Ph.D. awarded 1990

3.  Member of graduate committees in the Department of Molecular and
    Cellular Biochemistry:\
    Jianyi Zhang, Ph.D. awarded 1992\
    Mark Janulis, Ph.D. awarded 1997\
    Anna Szpaderska, Ph.D. awarded 2000

4.  Member of graduate committees in the Molecular Biology Program:\
    Sanjay D'Souza, Ph.D. awarded 2002

5.  Member of graduate committee in the Department of Cell Biology,
    Neuroscience and Anatomy\
    Doug Faunce, Ph.D. awarded 1998\
    Meredith Kamradt, Ph.D. awarded 2000\
    Meredith Gregory, Ph.D. awarded 2000

6.  Member of graduate committee in the Department of Pharmacology\
    Rashid Rashid, M.D./PhD. Awarded 2007

**Other Past Mentorship at Hines VA Hospital and Loyola University**:

1.  Mentor for Science Hines VA Hospital Student Fellowship Awardees:\
    Michael Coogan (1988 - 1992)\
    Yvonne Lozano (1988 - 1992)\
    Andelka Djordjevic (1992 - 1996)\
    Janet Benefield: (1995 - June 1996)\
    Dragana Djordjevic (1997 - 1998)\
    Nancy Ziroli (1996 - 1999)\
    Lea Lim (1997-1999)\
    Snehal Patel: (1996-2000)\
    Gwen Wera (1998-2003)\
    Juan Ortega (2001-2003)\
    Beth Kessler (2002-2003)

2\. Joe Kut: Department of Psychiatry, Loyola University, medical
student conducting studies in Biological Psychiatry Psycho-Immunology
(September 1990 - November 1992); Resident Fellow at Rush Presbyterian
Hospital conducting studies in Biological Psychiatry (August 1994 - June
1996).

3\. Loyola University Medical Student Research Fellows\
John Halpin: (June 1992 - July 1993)\
Tatyana Farietta: (September 1993 - August 1994)

4\. First Year Medical Student Summer Researchers:\
Jeannie Wang, Gayle McCloskey and Susan Charboneau (1993)\
Michelle Montpetitte and Gigi Ip (1994)\
Derik West and Imrana Malik (1995)\
Luke Halbur (1996)\
Anil Shah and Sarita Keni, (1997)\
Eve Lubbers (1998)

5, Teach Molecular Biology and Protein Chemistry Workshops for
undergraduate students enrolled in the Biochemistry course at Rosary
College. Workshops conducted at Hines VA Hospital (1991-1997)

6\. Medical Research Associates:\
Rubina Hussain, M.D. (September 1992 - July 1993)\
Arain Javed, M.D. (summer 1994)\
Safewat Eskandar, M.D. (1994-1995)\
Shreyash Pandya, M.D. (1996-1997)

7\. Department of Otolaryngology, Loyola University Residents on
Research Rotations:\
Ari Taitz, M.D. (July 1994 - February 1995)\
Abhay Vaydia, M.D. (July 1995 - October 1995)\
Mary Totten, M.D. (November 1995 - February 1996)\
Joe Donzelli, M.D. (March 1996 - June 1996)\
Ari Taitz, M.D. (July 1996 - October 1997 1996)\
Thomas Garrity, M.D. (November 1996 - February 1997)\
Rajiv Pandit, M.D. (July 1996 - March 1997)\
Landon Riggs, M.D. (March 1997 - June 1997)\
Kevin Cavanaugh, M.D. (July 1997 - October 1997)\
Bobby Mukkamali, M.D. (November 1997 - February 1998)\
Steven Gabel, M.D. (March 1998 - June 1998\
Chris Witt, M.D. (July 1998 -- October 1998)\
Sarah Fowler, M.D. (November 1998 -- February 1999)\
Rajiv Pandit, M.D. (March 1999 -- June 1999)\
Brian Wachter, M.D. (July 1999 -- October 1999)\
Christopher Hampton, M.D. (November 1999 -- February 2000)\
John Brockenbrough, M.D. (March 2000 -- June 2000)\
Kevin Hulett, M.D. (July 2000 -- October 2000)\
George Moynihan, M.D. (November 2000 -- February 2001\
Atul Vaidya, M.D. (March 2001 -- June 2001)\
James Banich, M.D. (July 2001 -- October 2001)\
Rob King, M.D. (November 2001 --February 2002)\
Curtis Walsh, M.D. (March 2002 -- June 2002)\
Alex Romashko, M.D. (July 2002 -- October 2002)

8\. Fourth Year Medical Student Research Rotation\
Sarah Fowler, Sebastian Scobercea, Jim Kalkanis, Greg Winters, Craig
Fischoff (1995)\
Mike Halburn and Rich Bergstrom (1996)\
Dan Madziarz (1997)\
Alison Ford (1998)\
Anthony Sparano (2001): received "American Academy of Otolaryngology --
Head and Neck Surgery Medical Student Award" for research paper)

9\. Postdoctoral Research Associates:\
Annettee Schmidt-Pak, Ph.D. (1992-1994)\
George D. Maier, Ph.D. (1992-1996)\
Raymond Metz, Ph.D. (1995-1998)\
Margaret Prechel, Ph.D.: (1994-1999)\
Deanne M.R. Lathers, Ph.D.: (1997-2001)\
Tamara Wrone-Smith, Ph.D.: (1999-2001)

10\. Mentor for students of the Illinois Mathematics and Science
Academy:\
Courtenay Diehl and Snigda Vallabhaneni: (1995-1996)\
Charley Ding and Erin Slone (1996-1997)\
Charley Ding and Irene Ma (1997-1998)\
Andrea Bonkowski and Adam Rojan (1998-1999)

11\. Mentor for Nelson Allen, Robert Wood Johnson fellow (Summer 1996).

12\. Mentor Student Research Assistants\
Yvonne Lozano: part-time Student Researcher (1992-1994); full-time
Research Assistant (1994-1996)\
Kristina Wiers: part-time Student Researcher (1995-1996); full-time
Research Assistant (1996-1998)\
Kathleen Bauler: Research Volunteer (1996-1999)\
Julie O'Donnell: Laboratory Research Technician (1998-1999)

13\. Summer Student Researchers, Hines VA Hospital\
Sandeep Devata (1993-1996)\
Jeremy Meisinger (1995-1996)\
Summa Devata (1996-1997)\
Janette Holub (1997)\
Kishore Vellody (1995-1998)\
Damien Stankiewicz (1999)\
Alyssa Beckmann (1999)

14\. Mentor for students on an NIH-sponsored minority student out-reach
program:\
Remy Washington and Fenesha Hubbard (1997).

16\. Carol Bier-Laning, M.D.: Mentor on her VA Career Development Award
(2001-2003)

15\. Deanne Ridley Lathers, Ph.D.: Mentored on her VA Entry-Level
Merit-Review Grant (2001-2005)

**Past Mentorship at the Medical University of South Carolina**:

1\. Co-mentor for VA Merit-Review Entry Level Program

Korey Johnson, Ph.D. (2005-2006)

2.  First Year Medical Student Summer Researchers:\
    Anna-Maria Clark, M.D./Ph.D. student (2007)

3.  Department of Otolaryngology, Medical University of South Carolina
    Residents on Research Rotations:\
    Josh Farrar, M.D. (July 2007 - October 2007)\
    Jonathan Kulbersh, M.D. (November 2007 - February 2008)

**CURRENT STUDENT MENTORSHIP:**

1\. Advisor for Students, Medical University of South Carolina\
Jennifer Konopa, Ph.D. program (2005-present)\
Adam Mailloux, Ph.D. program (2005-present)\
Jarrett Walsh, M.D./Ph.D. program (2005-present)\
Anna-Maria Clark, M.D./Ph.D. program (2007-present)

3\. Co-mentor for Junior-Level Faculty\
Amanda Larue, Ph.D. (2005-2008) --Merit-Review Entry Level Program

Betsy Hill, Ph.D. (2006-2010) -- NIH Training Grant

Christopher H. Parsons, M.D. (2006-2011) -- VA Career Development Award
(pending)

4\. Department of Otolaryngology, Medical University of South Carolina
Resident on Research Rotations: none at present

**EXTRAMURAL INVITED LECTURER (A few representative lectures listed)**:

1.  Tumor stimulation of myelopoiesis and the resultant appearance of
    bone marrow-derived immune suppressor cells. 2nd International
    Meeting of Anticancer Res., Saronis, Greece, October 13, 1988.

2.  Lessening of myelopoiesis and the associated bone marrow-derived
    immune suppressor cells in tumor bearers by interferon-γ and tumor
    necrosis factor-α. 2nd International Meeting of Anticancer Res.,
    Saronis, Greece, October 13, 1988.

3.  Mechanisms of immune suppression in tumor-bearing mice. Hokkaido
    University Cancer Institute, Sapporo Japan, September 10, 1989.

4.  Use of cytokine therapy to eliminate immune suppressor cells.
    Hayashibara Biochemical labs, Okayama, Japan, September 14, 1989.

5.  Role of prostaglandin E~2~ in stimulating tumor metastasis. Toyama
    Medical and Pharmaceutical University, Toyama, Japan, September 17,
    1989.

6.  Myelopoiesis-associated immune suppressor cells in tumor bearers.
    International Congress of Leukocyte Biology, Crete, Greece, October
    14, 1990.

7.  Myelopoiesis stimulates metastatic properties of cancer cells.
    Michigan Cancer Institute, Detroit, MI, June 22, 1991.

8.  Flow cytometric analysis for immune suppressive GM-progenitor cells.
    Department of Biological Physics, Moscow University, Moscow, Russia,
    September 12, 1991.

9.  Regulation of tumor-induced myelopoiesis by PGE~2~. Mid-Winter
    Meeting of the Prostaglandin Society, Keystone, CO, January 19,
    1993.

10. Tumor responsiveness to the metastasis-stimulatory effects of
    prostaglandin E~2~ is restricted by protein phosphatases. 3rd
    International Conference on Eicosanoids and Other Bioactive Lipids
    in Cancer, Inflammation and Radiation Injury, Washington, D.C.,
    October 14, 1993.

11. Protein phosphatases-1 and -2A regulate tumor cell migration,
    invasion, and cytoskeletal organization. 4th International
    Conference on Eicosanoids and Other Bioactive Lipids in Cancer,
    Inflammation and Radiation Injury. Hong Kong, October 6, 1995.

12. Role of microglia in Alzheimer's Disease. Procter & Gamble-Miami
    Valley Center, Cincinnati, OH, March 31, 1996.

13. GM-progenitor cells: Friend or Foe? University of Nebraska Medical
    Center at Omaha. Pathology Grand Rounds. September 25, 1996.

14. Immune suppressive GM-progenitor cells: Smith-Kline. November 18,
    1997.

15. CD34^+^ cells: fried or foe? Finch University of Health Sciences /
    The Chicago Medical School. February 1999.

16. Tumor immunology -- from the bench to the clinic. Grand Rounds,
    Department of Otolaryngology, University of Michigan, Ann Arbor.
    July 22, 1999.

17. CD34^+^ progenitor cells in tumor bearers. Grand Rounds, Department
    of Gastroenterology, University of Illinois at Chicago, January 17,
    2000.

18. How to have it all. Association for Women in Science -- Chicago Area
    Chapter, February 10, 2000

19. CD34^+^ progenitor cells in cancer patients. Grand Rounds, Moffitt
    Cancer Center, Tampa, FL, October 3, 2001.

20. Tumor mobilization and skewing of the differentiation of CD34^+^
    progenitor cells. Medical Grand Rounds, Medical University of South
    Carolina, Charleston, SC, August 9, 2004.

21. Translating studies on cancer progression into therapeutic
    strategies. Medical University of South Carolina first year graduate
    program. October 24, 2006.

22. CD34^+^ cells: immune regulation, tumor progression, and beyond.
    Medical Grand Rounds, University of Nebraska, Omaha, NE, June 18,
    2007.

**invited PARTICIPANT IN MEETINGS: (representative sample)**

1.  Invited to chair session on \"Kinases and Phosphatases\" at the 3rd
    International Conference on Eicosanoids and Other Bioactive Lipids
    in Cancer, Inflammation and Radiation Injury. Washington, D.C.,
    October 14, 1993.

2.  Invited to chair session on \"Cell Growth\" at the 4rd International
    Conference on Eicosanoids and Other Bioactive Lipids in Cancer,
    Inflammation and Radiation Injury. Hong Kong, October 4, 1995.

3.  Invited to chair session on \"Tumor Antigen Presentation,
    Costimulation, Normal and Abnormal T‑cell Activation Minisymposium
    \" at the American Association for Cancer Research Meeting. San
    Diego, April 14, 1997.

4.  Invited to present course entitled "Clinically Relevant Tumor
    Immunology" at the annual meeting of the American Academy of
    Otolaryngology-Head and Neck Surgery, September 15, 1998, San
    Antonio, TX

5.  Invited to chair session on \"Immunotherapy of Cancer \" at the
    American Association of Immunologists Meeting. Washington D.C.,
    April 17, 1999.

6.  Invited panelist for the 5^th^ International Conference on Head and
    Neck Cancer. San Francisco, CA. July 29-August 2, 2000.

7.  Invited to chair session on "Cancer Immunology" at the American
    Association of Immunologists Meeting. Miami Beach, FL, May 21, 2007.

**BIBLIOGRAPHY:**

**PUBLICATIONS in peer-reviewed journals:**

1.  **Ivanoff** (**Young**), M.R., and Renshaw, H.W. Weak calf syndrome:
    serum immunoglobulin concentrations in precolostral calves. Am. J.
    Vet. Res. *36*:1129-1134, 1975.

2.  **Young**, M.R. and McIvor, K,L. Enhancement of thymus cell function
    by macrophage culture supernatants. J. Reticuloendothel. Soc.
    *27*:39-47, 1980.

3.  **Young**, M.R., Cheung, H.T. and Sundharadas, G. Selective
    inhibition of tumor cell migration by culture supernatants derived
    from normal and lipopolysaccharide activated macrophages. J.
    Reticuloendothel. Soc. *27*:143-150, 1980.

4.  **Young**, M.R., Sundharadas, G., Cantarow, W.D. and Kumar, P.R.
    Purification and functional characterization of a low molecular
    weight immune modulating factor produced by Lewis lung carcinoma.
    Int. J. Cancer *30*:517-524, 1982.

5.  **Young**, M.R. and Henderson, S. Enhancement in immunity of tumor
    bearing mice by immunization against prostaglandin E~2~. Immunol.
    Comm. *11*:345-356, 1982.

6.  **Young**, M.R. and Dizer, M. Enhancement of immune function and
    tumor growth inhibition by antibodies against prostaglandin E~2~.
    Immunol. Comm. *12*:11-23, 1983.

7.  **Young**, M.R. and Knies, S. Prostaglandin E production by Lewis
    lung carcinoma: Mechanism for tumor establishment *in vivo*. J.
    Natl. Cancer Inst. *72*:919-922, 1984.

8.  **Young**, M.R. and Simmermaker, J. Prostaglandin E~2~ regulates
    production of tumoristatic factors by macrophage-like P388D1
    cells. J. Natl. Cancer Inst. *73*:959-962, 1984.

9.  Mahan, M., Meunier, J., Newby, M. and **Young**, M.R. Prostaglandin
    E~2~ production by EL4 leukemia cells: Mechanism for tumor
    dissemination. J. Natl. Cancer Inst. *74*:191-195, 1985.

10. **Young**, M.R., Meunier, J. and Newby, M. Relationships between
    morphology, dissemination, migration and prostaglandin E~2~
    secretion by cloned variants of Lewis lung carcinoma. Cancer Res.
    *45*:3918-3923, 1985.

11. **Young**, M.R. and Newby, M. Enhancement of tumor cell migration by
    prostaglandin E~2~ produced by macrophages. Cancer Res.
    *46*:160-164, 1986.

12. **Young**, M.R., Wheeler, E. and Newby, M. Macrophage-mediated
    suppression of natural killer cell activity in mice bearing Lewis
    lung carcinoma. J. Natl. Cancer Inst. *76*:745-750, 1986.

13. Nikcevich, D.A., **Young**, M.R., Ellis, N.K., Newby, M. and Wepsic,
    H.T. Stimulation of hematopoiesis in untreated and cyclophosphamide
    treated mice by the inhibition of prostaglandin synthesis. J.
    Immunopharmacol. *8*:299-313, 1986.

14. **Young**, M.R. and Hoover, C.S. Inhibition of the spleen cell
    cytotoxic capacity toward tumor by the elevated prostaglandin E~2~
    levels in mice bearing Lewis lung carcinoma. J. Natl. Cancer Inst.
    *77*:425-429, 1986.

15. **Young**, M.R. and Newby, M. Differential induction of suppressor
    macrophages by cloned Lewis lung carcinoma variants. J. Natl. Cancer
    Inst. *77*:1255-1260, 1986.

16. Ellis, N.K., **Young**, M.R., Nikcevich, D.A., Newby, M. and Wepsic,
    H.T. Stimulation of prostaglandin dependent macrophage suppressor
    cells by the subcutaneous injection of polyunsaturated fatty acids.
    Cell. Immunol. *102*:251-260, 1986.

17. **Young**, M.R., Newby, M. and Wepsic, H.T. Hematopoiesis and
    suppressor bone marrow cells in mice bearing large metastatic Lewis
    lung carcinoma tumors. Cancer Res. *47*:100-105, 1987.

18. **Young**, M.R., Duffie, G.P. and Newby, M. Adhesiveness and
    morphology of Lewis lung carcinoma variants influence their
    sensitivity to natural killer cytolysis and their metastatic
    capacity. Invasion Met. *7*:96-108, 1987.

19. **Young**, M.R., Ellis, N.K., Young, M.E. and Wepsic, H.T.
    Stimulation of hematopoiesis and bone marrow suppressor cells by the
    subcutaneous injection of linoleic acid. Cell. Immunol.
    *107*:238-248, 1987.

20. **Young**, M.R., Young, M.E. and Wepsic, H.T. The effect of
    prostaglandin E~2~-producing nonmetastatic LLC cells on the
    migration of prostaglandin E~2~-responsive metastatic LLC cells.
    Cancer Res. *47*:3679-3683, 1987.

21. **Young**, M.R., Endicott, R.A., Duffie, G.P. and Wepsic, H.T.
    Suppressor alveolar macrophages in mice bearing Lewis lung carcinoma
    tumors. J. Leuko. Biol. *42*:682-688, 1987.

22. Nikcevich, D.A., Duffie, G.P., **Young**, M.R., Ellis, N.K.,
    Kaufman, G.E. and Wepsic, H.T. Stimulation of suppressor cells in
    the bone marrow and spleens of high dose cyclophosphamide treated
    C57Bl/6 mice. Cell. Immunol. *109*:349-359, 1987.

23. **Young**, M.R., Young M.E. and Wepsic, H.T. The effect of
    recombinant interferon-γ on the hematopoietic and immunological
    parameters of mice bearing metastatic Lewis lung carcinoma tumors.
    Exp. Hematol. *16*:295-301, 1988.

24. **Young**, M.R., Young, M.E. and Kim, K. Regulation of tumor-induced
    myelopoiesis and the associated immune suppressor cells in mice
    bearing metastatic Lewis lung carcinomas by prostaglandin E~2~.
    Cancer Res. *48*:6826-6831, 1988.

25. Duffie, G.P., Romanelli, R.R., Ellis, N.K., **Young**, M.R. and
    Wepsic, H.T. The effect of E series prostaglandins on blastogenic
    responses *in vitro* and graft vs. host responses *in vivo*.
    Immunopharmacol. Immunotoxicol., *10*:597-615, 1988

26. Mahan, M.P. and **Young**, M.R. Immune parameters of
    exercise-stressed and exercise-conditioned rats. J. Appl. Physiol.
    *66*:282-287, 1989.

27. **Young**, M.R., Aquino, S. and Young, M.E. Differential induction
    of hematopoiesis and immune suppressor cells in the bone marrow
    versus in the spleen by Lewis lung carcinoma variants. J. Leuko.
    Biol. *45*:262-273, 1989.

28. **Young**, M.R., Young, M.E. Effects of fish oil diets on
    prostaglandin-dependent and myelopoiesis-associated immune
    suppressor mechanisms of mice bearing metastatic Lewis lung
    carcinoma tumors. Cancer Res. *49*:1931-1936, 1989.

29. Ellis, N.K., Duffie, G.P., **Young**, M.R., Wepsic, H.T. The effects
    of 16, 16-dimethyl PGE~2~ and phosphodiesterase inhibitors on Con-A
    blastogenic responses and NK cytotoxic activity of mouse spleen
    cells. J. Leuko. Biol., *47*:371-377, 1990.

30. **Young**, M.R.I., Duffie, G.P., Lozano, Y., Young, M.E., Wright,
    M.A. Association of a functional prostaglandin E~2~- (PGE~2~)
    protein kinase A coupling with responsiveness of metastatic Lewis
    lung carcinoma (LLC) variants to PGE~2~ and to PGE~2~-producing
    nonmetastatic LLC variants. Cancer Res., *50*:2973-2978, 1990.

31. **Young**, M.R.I., Young, M.E., Wright, M.A. Myelopoiesis-associated
    suppressor cell activity in mice with Lewis lung carcinoma tumors:
    interferon-γ plus tumor necrosis factor-α synergistically reduce
    suppressor cell activity. Int. J. Cancer, *46*:245-250, 1990.

32. **Young**, M.R.I. Modulation of eicosanoid biosynthesis and
    inhibition of substrate availability for phospholipase A~2~ by a
    modified hexose sugar, amiprilose hydrochloride. Prostaglandins,
    *40*:35-49, 1990.

33. **Young**, M.R.I., Young, M.E., Wright, M.A. Stimulation of immune
    suppressive bone marrow cells by colony stimulating factors. Exp.
    Hematol., *18*:806-811, 1990.

34. Duffie, G.P, and **Young**, M.R.I. Tumoricidal activity of alveolar
    and peritoneal macrophages of C57Bl/6 mice bearing metastatic or
    nonmetastatic variants of Lewis lung carcinoma. J. Leuko. Biol.,
    *49*:8-14, 1991.

35. Rahman, M.A., Sauter, D.C., **Young**, M.R. Effects of dietary fish
    oil on the induction of experimental membranous nephrophathy in the
    rat. Lab. Invest., *64*:371-376, 1991.

36. **Young**, M.R.I., Okada, F., Tada, M, Hosokawa, M., Kobayashi, H.
    Association of increased tumor cell responsiveness to prostaglandin
    E~2~ with more aggressive tumor behavior. Invasion Met., *11*:48-57,
    1991.

37. **Young**, M.R.I., Wright, M.A., Young, ME.: Antibodies to
    colony-stimulating factors block Lewis lung carcinoma
    cell-stimulation of immune suppressive bone marrow cells. Cancer
    Immunol. Immunother., *33*:146-152, 1991.

38. Azad, N., Jurgens, J., **Young**, M.R., Reda, D., Duffner, L.,
    Kirsteins, L., Emanuele, N.V., Lawrence, A.M. Presence of
    luteinizing hormone-releasing hormone in rat thymus. Prog.
    NeuroEndocrinImmunol., *4*:113-120, 1991.

39. **Young**, M.R.I., Young, M.E., Lozano, Y., Coogan, M., Bagash, J.M.
    Regulation of protein kinase A activation and prostaglandin
    E~2~-stimulated migration of Lewis lung carcinoma clones. Int. J.
    Cancer, *49*:150-155, 1991.

40. **Young**, M.R.I, Lozano, Y., Coogan, M., Wright, M.A., Young, M.E.,
    Bagash, J.M. Stimulation of the metastatic properties of Lewis lung
    carcinoma cells by autologous granulocyte-macrophage
    colony-stimulating factor. Int. J. Cancer, *50*:628-634, 1992.

41. **Young**, M.R.I., Wright, M.A., Coogan, M., Young, M.E., Bagash, J.
    Tumor-derived cytokines induce bone marrow suppressor cells which
    mediate immune suppression through transforming growth factor β.
    Cancer Immunol. Immunother., *35*:14-18, 1992.

42. Goto, M., Yoshioka, T., **Young**, R., Gottschalk, M.E., Anderson,
    C.L., Zeller, W.P. Early endotoxin tolerance in suckling rats. Res.
    Comm. Chem. Pathol. Pharmacol., *76*:249-252, 1992.

43. Kut, J.L., **Young**, M.R.I., Crayton, J.W., Wright, M.A., Young,
    M.E. Regulation of murine T-lymphocyte function by spleen
    cell-derived and exogenous serotonin. Immunopharmacol.
    Immunotoxicol., *14*:783-796, 1992.

44. **Young**, M.R.I., Wright, M.A. Myelopoiesis-associated immune
    suppressor cells in mice bearing metastatic Lewis lung carcinoma
    tumors: *In vivo* use of interferon-γ plus tumor necrosis factor-α
    to synergistically reduce immune suppressor and tumor
    growth-promoting activities of bone marrow cells, and to diminish
    tumor recurrence and metastasis. Cancer Research, *52*:6335-6340,
    1992

45. **Young**, M.R.I., Young, M.E., Lozano, Y., Bagash, J.M. Activation
    of protein kinase A increases the *in vitro* invasion, migration and
    adherence to reconstituted basement membrane by Lewis lung carcinoma
    tumor cells. Invasion Met., *12*:253-263, 1992.

46. **Young**, M.R.I., Lozano, Y., Djordjevic, A., Devata, S., Matthews,
    J., Young, M.E., Wright, M.A. Granulocyte-macrophage
    colony-stimulating factor stimulates the metastatic properties of
    Lewis lung carcinoma cells through a protein kinase A signal
    transduction pathway. Int. J. Cancer, *53:* 667-671, 1993.

47. **Young**, M.R.I., Lozano, Y., Djorjevic, A., Maier, D. Protein
    phosphatases limit tumor motility. Int. J. Cancer, *54*: 1036-1041,
    1993.

48. Yoshioka, T., Goto, M., Kodama, M. Gottschalk, M.E., Anderson, C.L.,
    **Young**, M.R.I., Zeller, W.P. J5 prevents endotoxin shock in
    suckling rats. Res. Comm. Chem. Pathol. Parmacol. *80*: 367-370,
    1993.

49. **Young**, M.R., Kut, J.L., Coogan, M.P., Wright, M.A., Young, M.E.,
    Matthews, J. Stimulation of splenic T-lymphocyte function by
    endogenous serotonin and by low dose exogenous serotonin.
    Immunology, *80*: 395-400, 1993.

50. **Young** , M.R.I., Halpin, J., Wang, J., Wright, M.A., Matthews,
    J., Schmidt Pak, A. 1α,25-dihydroxyvitamin D~3~ plus interferon-γ
    block lung tumor production of granulocyte-macrophage
    colony-stimulating factor and induction of immune suppressor cells.
    Cancer Res., *53*: 6006-6010, 1993.

51. **Young**, M.R.I., Halpin, J., Hussain, R., Lozano, Y., Djordjevic,
    A., Devata, S., Matthews, J., Wright, M.A. Inhibition of tumor
    production of granulocyte-macrophage colony-stimulating factor by
    1α,25-dihydroxyvitamin D~3~ reduces tumor motility and metastasis.
    Invasion Met., 13: 169-177, 1993.

52. **Young**, M.R.I., McCloskey, G., Wright, M.A., Schmidt Pak, A.
    Increasing infiltration and activation of CD8^+^ tumor-infiltrating
    lymphocytes after eliminating immune suppressive
    granulocyte-macrophage progenitor cells with low doses of
    interferon-γ plus tumor necrosis factor-α. Cancer Immunol.
    Immunother, *38*:9-15, 1994.

53. **Young**, M.R.I., Charboneau, S., Lozano, Y., Djordjevic, A.,
    Young, M.E. Activation of the protein kinase A signal transduction
    pathway by granulocyte-macrophage colony-stimulating factor or by
    genetic manipulation reduces cytoskeletal organization in Lewis lung
    carcinoma variants. Int. J. Cancer, *54*:446-451, 1994.

54. Goto, M., Yoshioka, T., Ravindranath, T., Battelino, T., **Young**,
    R.I., Zeller, W.P. LPS injected into the pregnant rat late in
    gestation does not induce fetal endotoxemia. Res. Commun. Mol.
    Pathol. Pharmacol., *85:* 109-112, 1994.

55. Schmidt-Pak, A., Wright, M.A., Matthews, J.P., Collins, S.L.,
    Petruzzelli, G., **Young**, M.R.I. Mechanisms of immune suppression
    in patients with head and neck cancer: Presence of immune
    suppressive CD34^+^ cells within cancers that secrete
    granulocyte-macrophage colony-stimulating factor. Clin. Cancer Res.,
    *1*:95-103, 1995.

56. **Young**, M.R.I., Matthews, J.P. Serotonin regulation of T-cell
    subpopulations and of macrophage accessory function. Immunology,
    *84*:148-152, 1995.

57. **Young**, M.R.I., Matthews, J.P., Kanabrocki, R.B., Sothern, B.,
    Roitman-Johnson, B., Scheving, L.E. Circadian rhythmometry of serum
    interleukin-2, interleukin-10, tumor necrosis factor-α and
    granulocyte-macrophage colony-stimulating factor in adult men.
    Chronobiology Int., *12*: 19-27, 1995.

58. Maier, G.D., Wright, M.A., Lozano, Y., Djordjevic, A., Matthews,
    J.P., **Young**, M.R.I. Regulation of cytoskeletal organization in
    tumor cells by protein phosphatases-1 and -2A. Int. J. Cancer, *61*:
    51-54, 1995.

59. **Young**, M.R.I., Farietta, T., Crayton, J.W. Brain production of
    nitric oxide and transforming growth factor-α. Mech. Ageing Dev.,
    *79*:115-126, 1995.

60. Schmidt-Pak, A., Ip, G., Wright, M.A., **Young**, M.R.I. Treating
    tumor-bearing mice with low dose interferon-γ plus tumor necrosis
    factor-α to diminish immune suppressive granulocyte- macrophage
    progenitor cells increases responsiveness to IL-2 immunotherapy.
    Cancer Res., *55*: 885-890, 1995.

61. **Young**, M.R.I., Montpetit, M., Lozano, Y., Djordjevic, A.,
    Devata, S., Matthews, J.P., Yedavalli, S., Cheijfec, G. Lewis lung
    carcinoma transfectants that either overexpress or have defective
    protein kinase A activity have a respective high or low capacity to
    invade and metastasize *in vivo*. Int. J. Cancer, *64*:104-109,
    1995.

62. Prechel, M.M., Lozano, Y., Wright, M.A., Ihm, J., **Young**, M.R.I.
    Ineffective immune enhancement by IL-12 in tumor-bearing mice whose
    immune depression is mediated by suppressive granulocyte-macrophage
    progenitor cells. Cancer Lett., *92*: 235-22, 1995.

63. Taitz, A., Petruzzelli, G., Pak, A.S., Wright, M.A., Matthews, J.P.,
    Raslan, W.F., Lozano, Y., **Young**, M.R.I. Immune parameters of
    mice bearing human head and neck cancer. Cancer Immunol.
    Immunother., *40*:283-291, 1995.

64. Sothern, R.B., Roitman-Johnson, B., Kanabrocki, E.L., Yager, J.G.,
    Roodell, M.M., **Young**, M.R., Nemchausky, B.M., Scheving, L.E.
    Circadian characteristics of circulating interleukin-6 in men. J.
    Allergy Clin. Immunol., *95*: 1029-1035, 1995.

65. **Young**, M.R.I., Ihm, J., Lozano, Y., Wright, M.A., Prechel, M.M.
    Treating tumor-bearing mice with vitamin D~3~ diminishes
    tumor-induced myelopoiesis and associated immune suppression, and
    reduces tumor metastasis and recurrence. Cancer Immunol.
    Immunother., *41*:37-45, 1995.

66. Sothern, R.B., Roitman-Johnson, B., Kanabrocki, E.L., Yager, J.G.,
    Fuerstenberg, R.K., Weatherbee, J.A., **Young**, M.R.I., Nemchausky,
    B.M., Scheving, L.E. Circadian characteristics of interleukin-6 in
    blood and urine of clinically healthy men. In vivo, *9*:331-340,
    1995.

67. Taitz, A, Petruzzelli, G.J., Lozano, Y., Shankar, R., **Young** ,
    M.R.I. Bi-directional stimulation of adherence to extracellular
    matrix components by human head and neck squamous carcinoma cells
    and endothelial cells. Cancer Lett., *96:*253-260, 1995.

68. Lozano, Y., Taitz, A., Petruzzelli, G.J., Djordjevic, A., Yedavalli,
    S., **Young**, M.R.I. Prostaglandin E~2~-protein kinase A signaling
    and protein phosphatases-1 and -2A regulate human head and neck
    squamous cell carcinoma motility, adherence to extracellular matrix
    components, and cytoskeletal organization. Prostaglandins, *51:*
    35-48, 1996.

69. **Young**, M.R.I., Wright, M.A., Matthews, J.P., Malik, I.,
    Prechel, M. Suppression of T‑cell proliferation by tumor-induced
    granulocyte-macrophage progenitor cells producing transforming
    growth factor-α and nitric oxide. J. Immunol., *156:*1916-1922,
    1996.

70. Maier, G.D., Vellody, K., Meisinger, J., Djordjevic, A., Lozano, Y.,
    **Young**, M.R.I. Protein kinase A regulates Lewis lung carcinoma
    metastasis and adherence to extracellular matrix components. Clin.
    Exp. Metastasis, *14*:314-322, 1996.

71. **Young**, M.R.I., Lozano, Y., Ihm, J., Wright, M.A., Prechel, M.M.
    Vitamin D~3~ treatment of tumor bearers can stimulate immune
    competence and reduce tumor growth when treatment coincides with a
    heightened presence of natural suppressor cells. Cancer Lett.,
    *104*:153-161, 1996.

72. Prechel, M.M., Lozano, Y., Wright, M.A., Ihm, J., **Young**, M.R.I.
    Immune modulation by interleukin-12 in tumor-bearing mice receiving
    vitamin D~3~ treatments to block induction of immune suppressor
    cells. Cancer Immunol. Immunother., *42*:213-220, 1996.

73. **Young**, M.R.I., Wright, M.A., Lozano, Y., Matthews, J.P.,
    Benefield, J., Prechel, M.M. Mechanisms of immune suppression in
    patients with head and neck cancer: influence on the immune
    infiltrate of the cancer. Int. J. Cancer, *67*:333-338, 1996.

74. Benefield, J., Petruzzelli, G.J., Fowler, S., Taitz, A., **Young**,
    M.R.I. Regulation of the steps of angiogenesis by human head and
    neck squamous cell carcinomas. Inv. Met., *16*:291-301, 1996.

75. Metz, R., Vellody, K., Patel, S., Bergstrom, R., Meisinger, J.,
    Jackson, J., Wright, M.A., Lozano, Y., **Young**, M.R.I. Vitamin
    D~3~ and ceramide reduce the invasion of tumor cells through
    extracellular matrix components by elevating protein phosphatase-2A.
    Inv. Met., *16*:280-290, 1996.

76. **Young**, M.R.I., Lozano, Y. Inhibition of tumor invasiveness by
    1α,25-dihydroxyvitamin D~3~ coupled to an increase in cytoskeletal
    organization and decline in protein kinase A activity. Clin. Exp.
    Met., *15*:102-110, 1997.

77. **Young**, M.R.I., Wright, M.A., Lozano, Y., Prechel, M.M.,
    Benefield, J., Leonetti, J.P., Collins, S.L., Petruzzelli, G.J.
    Increased recurrence and metastasis in patients whose primary head
    and neck squamous cell carcinomas secreted granulocyte-macrophage
    colony-stimulating factor and contained CD34^+^ natural suppressor
    cells. Int. J. Cancer, *74:*69-74, 1997.

78. Meisinger, J., Patel, S., Vellody, K., Bergstrom, R., Benefield, J.,
    Lozano, Y., **Young**, M.R.I. Protein phosphatase-2A association
    with microtubules and its role in restricting the invasiveness of
    human head and neck squamous cell carcinoma cells. Cancer Lett.,
    *111*:87-95, 1997.

79. Prechel, M.M., Halbur, L., Vaidya, A.M., Devata, S., **Young**,
    M.R.I. Increased interleukin‑6 production by cerebral cortical
    tissue of adult versus young mice. Mech. Ageing Dev., *92*:185-194,
    1997.

80. Wiers, K., Lozano, Y., Messingham, K.A.N., Metz, R., **Young**,
    M.R.I. 1α,25-dihydroxyvitamin D~3~ differentially regulates
    activation of normal T-cells versus T‑cells of tumor bearers through
    protein phosphatase‑2A. Cancer Immunol. Immunother., *44*:97-102,
    1997.

81. Vaidya, A.M., Chow, J.M., Stankiewicz, J.A., Mathews, H.L.,
    **Young**, M.R.I. Correlation of middle meatal to maxillary sinus
    culture. Am. J. Rhinology, *11:*139-143 1997.

82. **Young**, M.R.I., Wright, M.A., Pandit, R. Myeloid differentiation
    treatment to diminish the presence of immune suppressive CD34^+^
    cells within human head and neck squamous cell carcinomas. J.
    Immunol. *159*:990-996, 1997.

83. NcNulty, J.A., Prechel, M.M., **Young**, M.R., Fox, L.M. Pinealocyte
    ultrastucture in mutant mice that lack sympathetic innervation to
    the pineal gland. J. Submicroscop. Cytol. Path., *29:*305‑311, 1997.

84. Goto, M., Yoshioka, T., **Young**, M.R.I., Battelino, T., Anderson,
    C.L., Zeller, W.P. A sublethal dose of LPS to pregnant rats induces
    TNF‑α tolerance in their 0-day old offspring. Am. Physiol. Soc.,
    :*273*:R1158-R1162, 1997.

85. Ravindranath, T., Yoshioka, Y., Goto, M., Issac, R., Goldman, G.,
    **Young**, M.R.I., Zeller, W.P. Endotoxin translocation following
    enteral refeeding in children. Clin. Pediatrics, *36*:523-528, 1997.

86. Petruzzelli, G.J., Benefield, J., Taitz, A..D., Fowler, S.,
    Kalkanis, J., Scobercea, S., West, D., **Young**, M.R.I. Heparin
    binding growth factor(s) derived from head and neck squamous cell
    carcinomas induce endothelial cell proliferation. Head and Neck,
    *19*:576-582, 1997.

87. Jackson, J., Meisinger, J., Patel, S., Lim, Z.C., Vellody, K., Metz,
    R., **Young**, M.R.I. Protein phosphatase‑2A associates with the
    cytoskeleton to maintain cell spreading and reduced motility of
    nonmetastatic Lewis lung carcinoma cells; the loss of this
    regulatory control in metastatic cells. Inv. Met., *17*:199-209,
    1997.

88. Benefield, J., Meisinger, J., Petruzzelli, G.J., **Young**, M.R.I.
    Endothelial cell response to human head and neck squamous cell
    carcinoma cells involves downregulation of protein
    phosphatases‑1/2A, cytoskeletal depolymerization and increased
    motility. Invasion Met., *17*:210-220, 1997

89. Garrity, T., Pandit, R., Wright, M.A., Benefield, J., Keni, S.,
    **Young**, M.R.I. Increased presence of CD34^+^ cells in the
    peripheral blood of head and neck cancer patients and their
    differentiation into dendritic cells. Int. J. Cancer, *73*: 663-669,
    1997.

90. **Young**, M.R.I. Protein phosphatases-1 and -2A regulate- tumor
    cell migration, invasion, and cytoskeletal organization. Adv. Exp.
    Med. Biol., *407:*311-318, 1997.

91. Donzelli, J., Leonetti, J.P., Bergstom, R.S., Wurster, R.D.,
    **Young**, M.R.I. Thermoprotective mechanisms of irrigation during
    bipolar cautery. Otolaryngol. - Head and Neck Surg., *119*:153-158,
    1998.

92. Wiers, K., Wright, M.A., Vellody, K., **Young**, M.R.I. Failure of
    tumor-reactive lymph node cells to kill tumor in the presence of
    immune suppressive CD34^+^ cells can be overcome with vitamin D~3~
    treatment to diminish CD34^+^ cell levels. Clin. Exp. Met., *16*:
    275-282,1998.

93. Wright, M.A., Wiers, K., Vellody, K., Djordjevic, D., **Young**,
    M.R.I. Stimulation of immune suppressive CD34^+^ cells from normal
    bone marrow by Lewis lung carcinoma tumors. Cancer Immunol.
    Immunother., *46*: 253-260, 1998.

94. Riggs, L.C., Shofner, W.P., Shah, A.R., Young, M.R.I., Hain, T.C.,
    Matz, G.J. Ototoxicity resulting from combined administration of
    metronidazole and gentamicin. Am. J. Otology, *2:* 430-434, 1999,

95. Gabel, S., Benefield, J., Mesinger, J., Petruzzelli, G.J.,
    **Young**, M.R.I. Protein phosphatases‑1 and --2A maintain
    endothelial cells in a resting state, limiting the motility that is
    needed for the morphogenic process of angiogenesis. Otolaryngology -
    Head and Neck Surgery, *121:* 463-468, 1999.

96. Lathers, D.M.R., Wright, M.A., Wiers, K.M., **Young**, M.R.I.
    Dendritic cell differentiation pathways of CD34^+^ cells from the
    peripheral blood of head and neck cancer patients. J. Leukocyte
    Biol., *65*: 623-628, 1999.

97. Young, M.R.I., Wright, M.A., Lathers, D.M.R., Messignham, K.A.
    Increased resistance to apoptosis by bone marrow CD34^+^ progenitor
    cells from tumor-bearing mice. Int. J. Cancer, 802: 609-615, 1999.

98. **Young**, M.R.I., Wright, M.A., Vellody, K., Lathers, D.M.R. Skewed
    differentiation of bone marrow CD34^+^ cells of tumor bearers from
    dendritic toward monocytic cells, and the reduction of
    differentiation toward dendritic cells by 1α,25-dihydroxyvitamin
    D~3~. Int. J. Immunopharmacol., 21: 675-688, 1999.

99. Lathers, D.M.R., Lubbers, E., Beal, N.M., Wright, M.A., **Young**,
    M.R.I. Cultures derived from peripheral blood CD34^+^ progenitor
    cells of head and neck cancer patients and from cord blood are
    functionally different. Human Immunol., 60: 1207-1215, 1999.

100. **Young**, M.R.I., Kolesiak, K., Wright, M.A., Gabrilovich, D.I.
     Chemoattraction of femoral CD34^+^ progenitor cells by
     tumor-derived vascular endothelial cell growth factor. Clin. Exp.
     Met., 17: 881-888, 1999.

101. Wiers, K.M., Wright, M.A. Lathers, D.M.R., **Young**, M.R.I.
     Vitamin D~3~ treatment to diminish the levels of immune suppressive
     CD34^+^ cells increases the effectiveness of adoptive
     immunotherapy. J. Immunother., 23: 115-124, 2000.

102. Donzelli, J, Leonetti, J.P., Wurster, R.D., Lee, J.M., **Young**,
     M.R.I. Neuroprotection when irrigation is included during bipolar
     cautery. Arch. Otolaryngol.-Head and Neck Surg., 126: 149-153,
     2000.

103. Prechel, M.M., Ding, C., Washington, R.L., Kolodziej, M.S.,
     **Young**, M.R.I. *In vivo* indomethacin treatment causes
     microglial activation in adult mice. Neurochem. Res., 25:357-362,
     2000.

104. Pandit, R., Garrity, T., Petruzzelli, G.J., Collins, S.L., Bastian,
     R.W., **Young**, M.R.I. CD34^+^ immune suppressor cells in the
     blood of head and neck cancer patients. Annals Otology, Rhinol.
     Laryngol., in 109:749-754, 2000.

105. Witt, C.J., Gabel, S.P., Meisinger, J., Werra, G., Liu, S.W.,
     **Young**, M.R.I. Inter-relationship between protein
     phosphatase--2A and the cytoskeletal architecture during the
     endothelial cell response to soluble products produced by human
     head and neck cancer. Otolaryngol -- Head Neck Surg., 122:721-727,
     2000.

106. **Young**, M.R.I., Petruzzelli, G.J., Kolesiak, K., Lathers, D.R.,
     Gabrilovich, D.I. Human squamous cell carcinomas of the head and
     neck chemoattract immune suppressive CD34^+^ progenitor cells.
     Human Immunol, 62: 332-341, 2001.

107. Kanabrocki, E.L., Hermida, R.C., Wright, M., **Young**, M.R.I.,
     Bremner, F.W., Third, J.L.H.C., Ryan, M.D., Ayala, D.E., Johnson,
     M., Nemchausky, B.A., Shirazi, P., Scheving, L.E., Olwin, J.H.
     Circadian variation of serum leptin in healthy and diabetic men.
     Chronobiol. Int., 18: 273-283, 2001.

108. Fowler, S.S., Leonetti, J.P., Banich, J.C., Lee, J.M., Wurster, R.,
     **Young**, M.R.I. Duration of neuronal stretch correlates with
     functional loss. Otolaryngol -- Head Neck Surg., 124: 641-644,
     2001.

109. **Young**, M.R.I., Liu, S.W., Meisinger, J. Differences in
     association of the serine/threonine protein phosphatase PP‑2A with
     microtubules of metastatic and nonmetastatic tumor cells. Clin.
     Exp. Met., 18: 407-413, 2001.

110. **Young**, M.R.I., Kolesiak, K., Achille, N.J., Meisinger, J.,
     Gonzalez, E., Liu, S.W., Wrone-Smith, T., Lathers, D.M.R. Impact of
     aging on immune modulation by tumor. Cancer Immunol. Immunother.,
     50: 315-320, 2001.

111. Lathers, D.M.R., Achille, N., Kolesiak, K., Hulett, K., Sparano,
     A., **Young**, M.R.I. Increased levels of immune inhibitory CD34^+^
     progenitor cells in the peripheral blood of patients with node
     positive head and neck cancer and the ability of the CD34^+^ cells
     to differentiate into antigen presenting dendritic cells.
     Otolaryngology -- Head Neck Surg., 125: 205-212, 2001.

112. Lathers, D.M.R., Clark, J.I., Achille, N.J., **Young**, M.R.I.
     Phase 1B study of 25‑hydroxyvitamin D~3~ treatment to diminish
     suppressor cells in head and neck cancer patients. Human Immunol.,
     62: 1282-1293, 2001.

113. Shafer, L.L., McNulty, J.A., **Young**, M.R.I. Assessment of
     metalonin's ability to regulate cytokine production by macrophage
     and microglia cell types. J. Neuroimmunol., 120: 84-93, 2001.

114. Jackson, J.L., **Young**, M.R.I. Protein phosphatase-2A modulates
     the serine and tyrosine phosphorylation of paxillin in Lewis Lung
     Carcinoma tumor variants. Clin. Exp. Metastasis, 19: 409-415, 2002.

115. **Young**, M.R.I., Kolesiak, K., Meisinger, J. Protein
     phosphatase‑2A regulates endothelial cell motility and both the
     phosphorylation as well as stability of focal adhesion complexes.
     Int. J. Cancer, 100: 276-282, 2002.

116. Wachter, B.G., Leonetti, J.P., Lee, J.M., Wurster, R.D., **Young**,
     M.R.I. Silver nitrate injury in the rat sciatic nerve: a model of
     facial nerve injury. Otolaryngol. -- Head Neck Surg., 127: 48-54,
     2002.

117. Banich, J.C., Kolesiak, K., **Young**, M.R.I. Chemoattraction of
     CD34^+^ progenitor cells and dendritic cells to the site of tumor
     excision as the first step of an immunotherapeutic approach to
     target residual tumor cells. J. Immunother., 26: 31-40, 2003.

118. **Young**, M.R.I., Liu, S.W., Meisinger, J. Protein phosphatase-2A
     restricts migration of Lewis lung carcinoma cells by modulating the
     phosphorylation of focal adhesion proteins. Int. J. Cancer, 103:
     38-44, 2003.

119. Shafer, L.L., McNulty, J.A., **Young**, M.R.I. Brain derived
     soluble factors differentially regulate BV2 microglia and
     peripheral macrophage immune function. NeuroImmunoModulation, 10:
     283-294, 2003.

120. Shafer, L.L., McNulty, J.A., **Young**, M.R.I. Brain activation of
     monocytes-lineage cells: involvement of interleukin (IL)-6.
     NeuroImmunoModulation, 10: 295-304, 2003.

121. Brockenbrough, J.M., Marzo, S., Wurster, R., **Young**, M.R.I. Bone
     wax prevents nystagmus following labyrinthine fenestration in
     guinea pigs. Otolaryngol. -- Head Neck Surg., 128: 726-731, 2003.

122. Jackson, J.L., **Young**, M.R.I. Protein phosphatase-2A regulates
     protein tyrosine phosphatase activity in Lewis lung carcinoma tumor
     variants. Clin. Exp. Metastasis, 20:357-364, 2003.

123. Lathers, D.M.R., Achille, N.J., **Young**, M.R.I. Incomplete Th2
     skewing of cytokines in plasma of patients with squamous cell
     carcinoma of the head and neck. Human Immunol., 64:1160-1166, 2003.

124. **Young**, M.R.I., Lathers, D.M.R. Increased aberrance of cytokine
     expression in plasma of patients with more advanced squamous cell
     carcinoma of the head and neck. Cytokine, 25:220-228, 2003.

125. **Young**, M.R.I. Tumor skewing of CD34^+^ progenitor cell
     differentiation into endothelial cells. Int. J. Cancer,
     109:516-524, 2004.

126. Lathers, D.M.R., Clark, J.I., Achille, N.J., **Young**, M.R.I.
     Phase 1B study to improve immune responses in head and neck cancer
     patients using escalating doses of 25‑hydroxyvitamin D~3~. Cancer
     Immunol. Immunother. 53: 422-430, 2004.

127. Sparano, A., Lathers, D.M.R., Achille, N.J., Petruzzelli, G.J.,
     **Young**, M.R.I. Modulation of Th1 and Th2 cytokine profiles and
     their association with advanced head and neck squamous cell
     carcinoma. Otolaryngol.-Head Neck Surg., 131: 573-576, 2004.

128. **Young**, M.R.I. Tumor-derived prostaglandin E~2~ and transforming
     growth factor-β stimulate endothelial cell motility through
     inhibition of protein phosphatase‑2A and involvement of PTEN and
     phosphatidylinositide 3-kinase. Angiogenesis, 7: 123-131, 2004.

129. Romashko A.A., **Young**, M.R.I. Protein phosphatase‑2A maintains
     focal adhesion complexes in keratinocytes and the loss of this
     regulation in squamous cell carcinomas. Clin. Exp. Metastasis, 21:
     371-379, 2004.

130. Rashid R.M., Achille, N.J., Lee, J.M., Lathers, D.M.R., **Young**,
     M.R.I. Decreased proliferation and skewed immune responses in
     LLC-bearing LLC mice. J. Environmental Pathol., Toxicol., Oncol.,
     24:175-192, 2005.

131. **Young**, M.R.I., Lathers, D.M.R. Combination docetaxel plus
     vitamin D~3~ as an immune therapy in animals bearing SCC VII/SF
     squamous cell carcinomas. Otolaryngol-Head Neck Cancer,
     133:611-618, 2005.

132. **Young**, M.R. Tumor skewing of CD34^+^ cell differentiation from
     a dendritic cell pathway into endothelial cells. Cancer Immunol.
     Immunotherapy, 55:558-569, 2006.

133. **Young**, M.R.I. Protective mechanisms of head and neck squamous
     cell carcinomas from immune assault. Head and Neck, 28:462-470,
     2006.

134. **Young**, M.R.I. Cytokine-containing gelfoam implants at a
     postsurgical tumor excision site to stimulate local immune
     reactivity. Int. J. Cancer, 119:133-138, 2006.

135. Rashid, R.M., Lee, J.M., Fareed, J., **Young**, M.R. In vivo
     heparan sulfate treatment alters the immune response of normal and
     LLC-bearing mice. Immunopharmacol. Immunotoxicol., 28:67‑79, 2006.

136. Woodworth BA, Lathers D, Neal JG, Skinner M, Richardson M,
     **Young** MR, Schlosser RJ. Immunolocalization of surfactant
     protein A and D in sinonasal mucosa. Am. J. Rhinology, 20:461-465,
     2006.

137. Kanabrocki, E.L., Hermida, R.C., Torossov, M., Haseman, M.B.,
     Bettis, K., **Young**, R.M.I., Mathew, J.P., Potkul, R., Hrushesky,
     W.J.M. Chronotherapy of ovarian cancer: effect on blood variables
     and serum cytokines. Clin. Ter. 157: 349-354, 2006.

138. Yen, K.L., Horner, M.J., Reed, S.G., Daguise, V.G., Bolick-Aldrich,
     S.W., **Young**, M.R., Day, T.A., Wood, P.A., Hebert, J.R. Head and
     neck cancer disparities in South Carolina: descriptive
     epidemiology, early detection, and special programs. J S C Med
     Assoc. 102: 192-200, 2006.

139. **Young**, M.R.I., Neville, B.W., Chi, A.C., Lathers, D.M.R.,
     Gillespie, M.B., Day, T.A. Oral premalignant lesions induce immune
     reactivity to both premalignant oral lesions and head and neck
     squamous cell carcinoma. Cancer Immunol. Immunother., 56:1077-1086,
     2007.

140. Gillespie, M.B., Moody, M.W., Lee, F.-S., Poole, L.J., Hornig, J.,
     Lathers, D., **Young**, M.R., Day, T.A. Head and neck cancer
     recurrence and mortality in non-selective cyclooxygenase inhibitor
     users. Arch. Otolaryngol. Head Neck Surg., 133(1):28-31, 2007.

141. Rashid, R.M., Lee, J.M., Fareed, J., **Young**, M.R.I. *In vitro*
     heparan sulfate modulates the immune responses of normal and
     tumor-bearing mice. Immunol. Invest., 36: 183-201, 2007.

142. Kanabrocki, E.L., Ryan, M.D., Lathers, D., Achille, N., **Young**,
     M.R.I., Cauteren, J.V., Foley, S., Johnson, M.C., Friedman, N.C.,
     Siegel, G., Nemchausky, B.A. Circadian distribution of serum
     cytokines in multiple sclerosis. Clin Ter . 158: 157-162., 2007.

143. **Young**, M.R.I., Neville, B.W., Chi, A.C., Lathers, D.M.R.,
     Gillespie, M.B., Day, T.A. Autocrine motility-stimulatory pathways
     of oral premalignant lesion cells. Clin. Exp. Metastasis, 24:
     131-139, 2007.

144. Walsh, J., Lathers, D.M.R., Chi, A.C., Gillespie, M.B., Day, T.A.,
     **Young**, M.R.I. Mechanisms of tumor growth and metastasis in head
     and neck squamous cell carcinoma. Curr. Treat. Options Oncol., 8:
     227-238, 2007.

145. Mulligan, J.K., Lathers, D.R.L., **Young**, M.R.I. Tumors skew
     endothelial cells to disrupt NK cell, T-cell and macrophage
     functions. Cancer Immunol. Immunother., 8: 227-238, 2008.

146. **Young**, M.R.I. Use of carcinogen-induced premalignant oral
     lesions in a dendritic cell-based vaccine to stimulate immune
     reactivity against both premalignant oral lesions and oral
     cancer. J. Immunother., 31: 148-156, 2008.

147. Kulbersh, J.S., Day, T.A., Gillespie, M.B., **Young**, M.R.I.
     1α,25-Dihydroxyvitamin D~3~ to skew intratumoral levels of immune
     inhibitory CD34^+^ progenitor cells into dendritic cells.
     Otolaryngology -- Head Neck Surg., in press, 2008.

148. Clark, J.I., Eisner, R.M., Hofmeister, C., Norton, J., Thomas, S.,
     Choudhury, A., Petruzzelli, G., Lathers, D., Young, M.R.I., Lau,
     A., Emami, B Phase I adjuvant radiation with docetaxel in high risk
     head and neck cancer. [JOURNAL]{.mark}

ADAM's PAPER

149. 

**chapters of books and invited papers in proceedings:**

1.  **Young**, M.R. and Newby, M. Differential induction of macrophage
    prostaglandin E~2~ secretion and suppressor activity by Lewis lung
    carcinoma variants. *In*: Prostaglandins and Cancer, E. Garaci, R.
    Paoletti and M.G. Santoro (eds.), Springer-Verlag, Berlin
    Heidelberg. pp. 273-276, 1987.

2.  **Young**, M.R. and Wepsic, H.T. Polyunsaturated fat-induced immune
    suppression: involvement of prostaglandin-producing suppressor
    cells. *In*: Carcinogenesis and Dietary Fat, S.Abraham (ed.),
    Martinus Nijhoff,- Boston. pp. 305-319, 1989.

3.  **Young**, M.R.I., Lozano, Y., Djordjevic, A., Maier, G.D., Young,
    M.E. Tumor responsiveness to the metastasis-stimulatory effects of
    prostaglandin E~2~ is restricted by protein phosphatases.
    Proceedings of the 3rd International Conference on Eicosanoids and
    Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury,
    1993.

4.  **Young**, M.R.I. Human squamous cell carcinomas of the head and
    neck chemoattract CD34^+^ progenitor cells and facilitate their
    differentiation into endothelial cells. Proceedings on Head and Neck
    Cancer, volume 5, pp. 127-132, 2000.

5.  Lathers, D.M.R., Achille, N., **Young**, M.R.I. Dendritic cell
    development from mobilized peripheral blood CD34^+^ cells. *In*:
    Methods in Molecular Medicine -- Cytokines and Colony Stimulating
    Factors. D. Korholz (ed.), Humana Press Inc.- Totowa, NJ. P.
    409-415, 2002.

**INVITED REVIEWS:**

1.  **Young**, M.R.I. Eicosanoids and the immunology of cancer. Cancer
    Metastatic Reviews, *13*:337-348, 1994.

2.  **Young**, M.R.I., Lathers, D.M.R. Myeloid progenitor cells mediate
    immune suppression in patients with head and neck cancers. Int. J.
    Immunopharmacol., *21:* 241-252, 1999.

```{=html}
<!-- -->
```
3.  **Young**, M.R.I. Review of "Chemokines and Cancer". *Ed:* B.
    Rollins. Arch. Pathol. Lab. Med *11:* 43, 2000.

4.  **Young**, M.R.I. Trials and tribulations of immunotherapy as a
    treatment option for patients with squamous cell carcinoma of the
    head and neck. Invited review. Cancer Immunol. Immunother., 53:
    375-382, 2004.

5.  Yen, K.L., Horner, M.J., Reed, S.G., Daguise, V.G., Bolick-Aldrich,
    S.W., **Young**, M.R., Day, T.A., Wood, P.A., Hebert, J.R. Head and
    neck cancer disparities in South Carolina: descriptive epidemiology,
    early detection, and special programs. J. S. C. Med. Assoc.
    102:192-200, 2006.

> **PENDING PEER-REVIEWED PUBLICATIONS:**

3.  Mulligan, J.K., Day, T.A., Gillespie, M.B., Rosenzweig, S.A.,
    **Young**, M.R.I. Secretion of VEGF by oral squamous cell carcinoma
    cells skews endothelial cells to suppress T‑cell functions.
    Submitted to Human Immunol., 2008.

**SELECT PUBLISHED ABSTRACTS AND PRESENTATIONS (74 of 131)**:

1.  **Young**, M.R. and Young, M.E. The effect of recombinant murine
    interferon-γ on the hematopoietic and immunological parameters of
    mice bearing metastatic Lewis lung carcinoma tumors. Conf. on
    Immunity to Cancer, Williamsburg, VA, November 9, 1987.

2.  Wepsic, H.T., Duffie, G.P., Ellis, N.K., Romanelli, R.J. and
    **Young**, M.R. The effects of polyunsaturated fatty acids (PUFA) on
    graft vs. host disease (GvHD). MidWest Autumn Immunol. Conf.,
    Chicago, IL, November 16, 1987.

3.  Sauter, D., **Young**, M.R., Rahman, M. The effect of high
    eicosapentaenoic acid diet (EPA) on immune complex
    glomerulonephritis (ICGN) in the rat. Kidney Int., *33*: 285, 1988.

4.  **Young**, M.R., Young, M.E., and Wepsic, H.T. Effect of dietary
    fish oil on Lewis lung carcinoma-induced hematopoiesis, immune
    suppression, and immune suppressor cells. FASEB J., *2*: Abstract
    #3222, 1988.

5.  **Young**, M.R., and Young, M.E. The effect of recombinant murine
    interferon-γ on the hematopoietic and immunological parameters of
    mice bearing metastatic Lewis lung carcinoma tumors. Proc. Am.
    Assoc. Cancer Res., *29*: Abstract #1453, 1988.

6.  **Young**, M.R., Young, M.E., and Kim, K. Tumor stimulation of
    myelopoiesis and the resultant appearance of bone marrow-derived
    immune suppressor cells. 2nd International Meeting of Anticancer
    Res., Saronis, Greece, October 13, 1988.

7.  Young, M.E., **Young**, M.R., and Kim, K. Lessening of myelopoiesis
    and the associated bone marrow-derived immune suppressor cells in
    tumor bearers by interferon-γ and tumor necrosis factor-α. 2nd
    International Meeting of Anticancer Res., Saronis, Greece, October
    13, 1988.

8.  **Young**, M.R., Young, M.E., and Kim, K. Regulation of
    tumor-induced myelopoiesis and the associated immune suppressor
    cells in mice bearing metastatic Lewis lung carcinomas by
    prostaglandin E~2~. J. Leukocyte Biol., *44*: Abstract #16, 1988.

9.  **Young**, M.R., and Young, M.E. Tumor-induced myelopoiesis and the
    associated immune suppressor cells. FASEB J., *3*: Abstract #1638,
    1989.

10. **Young**, M.R., Young, M.E., and Duffie, G.P. Prostaglandin E~2~
    responsiveness of Lewis lung carcinoma variants. Proc. Am. Assoc.
    Cancer Res., *30*: Abstract #342, 1989.

11. **Young**, M.R., Young, M.E., and Wright, M.A. Interferon-γ and
    tumor necrosis factor-α synergistically reduce
    myelopoiesis-associated immune suppressor cells in tumor bearers.
    FASEB J., *4*: Abstract #60094, 1990.

12. **Young**, M.R., Young, M.E., and Wright, M.A. Stimulation of immune
    suppressive bone marrow cells by tumor factors and by colony
    stimulating factors. Cancer Res., *50*: Abstract #1787, 1990.

13. **Young**, M.R.I., Young, M.E., and Wright, M.A. Stimulation of
    immune suppressor cells by tumor secretion of colony stimulating
    factors. J. Leuko. Biol., *S.1*: Abstract #76, 1990.

14. Bagash, J.M., **Young**, M.R.I. Regulation of c-myc expression in
    metastatic Lewis lung carcinoma cells by protein kinase. FASEB J.,
    *4*: Abstract #2990, 1991.

15. **Young**, M.R.I., Wright, M.A., Coogan, M. Tumor-derived GMCSF and
    IL3 induce bone marrow suppressor cells which mediate immune
    suppression via IFN‑α and TGF‑β. FASEB J., *4*: Abstract #6327,
    1991.

16. **Young**, M.R., Young, M.E., Wright, M.A. Prostaglandin
    E~2~-stimulated metastasis: mechanisms for hyperactivation of
    protein kinase A in metastatic vs. nonmetastatic Lewis lung
    carcinoma clones. Proc. Am. Assoc. Cancer Res., *50*: Abstract #398,
    1991.

17. Kut, J.L., **Young**, M.R.I., Crayton, J.W., van de Kar, L., Arora,
    R.C. Regulation of murine T-lymphocyte function by endogenous
    serotonin. Neuroscience, Abstract #3039, 1991.

18. Azad, N., Emanuele, N.V., La Paglia, N., **Young**, M.R., Crayton,
    J.W., Lawrence, A.M. Epinephrine and norepinephrine effects on
    spleen lymphocyte blastogenesis. Neuroscience, 1991.

19. **Young**, M.R.I., Wright, M.A. Interferon-γ plus tumor necrosis
    factor-α diminish the presence of tumor-induced bone marrow immune
    suppressor cells and reduce metastasis. FASEB J., *6*: Abstract
    #4362, 1992.

20. Bagash, J., **Young**, M.R.I. Modulation of metastasis in Lewis lung
    carcinoma cells by tumor necrosis factor-α and interferon-γ. FASEB
    J., *6*: Abstract #2446, 1992.

21. Lozano, Y., Bagash, J., Young, M.E., Coogan, M., Wright, M.A.,
    **Young**, M.R.I. Activation of protein kinase A stimulates tumor
    metastasis. FASEB J., *6*: Abstract #2448, 1992.

22. Wright, M.A., Bagash, J., **Young**, M.R.I. Tumor necrosis factor-α
    and interferon-γ modulate the biological properties of Lewis lung
    carcinoma cells. FASEB J., *6*: Abstract #2447, 1992.

23. **Young**, M.R.I., Lozano, Y., Young, M.E., Wright, M.A., Coogan,
    M., Bagash, J. Stimulation of tumor metastasis by
    granulocyte-monocyte colony-stimulating factor. Proc. Am. Assoc.
    Cancer Res., *52*: Abstract #319, 1992.

24. Goto, M., Yoshioka, Y., **Young**, M.R.I., Gottschalk, M.E.,
    Anderson, C.L., Zeller, W.P. Endotoxin tolerance in newborn rats.
    Conference on Shock, Santa Fe, New Mexico, 1993.

25. **Young**, M.R.I., Lozano, Y., Djordjevic, A., Devata, S., Matthews,
    J., Young, M.E., Wright, M.A. GM-CSF stimulates the metastatic
    properties of Lewis lung carcinoma cells through PKA signal
    transduction pathway. FASEB J., Abstract #40074, 1993.

26. **Young**, M.R.I., Wright, M.A., Young, M.E., Matthews, J.,
    Halpin, J. Immune suppressive GM-progenitor cells in
    GM-CSF-producing lung cancers. J. Immunol, *150*: Abstract #495,
    1993.

27. Azad, N., LaPaglia, N., Wright, M.A., Williams, D.W., Lawrence,
    A.M., **Young**, M.R. Luteinizing hormone releasing hormone (LHRH)
    decreases natural killer (NK) cell cytolytic activity. Endocrine
    Society Meeting, Abstract #1567, 1993.

28. **Young**, M.R.I., Lozano, Y., Djordjevic, A., Maier, G.D. Tumor
    responsiveness to the metastasis-stimulatory effects of
    prostaglandin E~2~ is restricted by protein phosphatases. 3rd
    International Conference on Eicosanoids and Other Bioactive Lipids
    in Cancer, Inflammation and Radiation Injury, Washington, D.C.,
    1993.

29. Gordon, P., Holland, L.E., **Young**, M.R.I. Suppression of HIV
    pathogenicity and apoptosis in lymphocytes by novel non-peptide
    inhibitors of protease. Selected for oral presentation at the 1st
    Int. Conf. on Applications of Apoptosis. La Jolla, California. 1994.

30. Roitman-Johnson, B., Southern, R.B., Kanabrocki, E.L., **Young**,
    R., Matthews, J., Yager, J.G., Krenz, M.M., Weatherbee, J.A.,
    Scheving, L.E. Circadian characteristics of circulating
    interleukin-6 in non-atopic men. Am. Acad. Allegy Immunol. 1994.

31. Schmidt Pak, A., Wright, M.A., McCloskey, G., **Young**, M.R.I.
    Activation of CD8^+^ tumor-infiltrating lymphocytes after
    eliminating immune suppressive granulocyte-macrophage progenitor
    cells. Am. Assoc. Cancer Res., San Francisco, CA 1994.

32. **Young**, M.R.I., Schmidt Pak, A., Wright, M.A., Collins, S.,
    Petruzzelli, G. Immune suppressive CD34^+^ cells in human head and
    neck cancers. FASEB J., Abstract #2737, 1994.

33. Roitman-Johnson, B., Sothern, R.B., Kanabrocki, E.L., Yager, J.G.,
    Roodell, M.M., Weatherbee, J.A., **Young**, M.R.I., Nemchausky,
    B.M., Shceving, L.E. Circadian characteristics of interleukin-6 in
    blood and urine of healthy adult men. 6th Int. Conf.
    Chronopharmacol. Chronother. 1994.

34. Taitz, A., Petruzzelli, G., Pak, A., Wright, M.A., **Young**, M.R.I.
    Immune parameters of mice bearing human head & neck cancer**.** Am.
    Assoc. Cancer Res., Toronto, Canada, 1995.

35. Kut, J.L., Matthews, J., Crayton, J.W., **Young**, M.R.I. The role
    of serotonin in human leukocyte function. FASEB, 1995.

36. **Young**, M.R.I., Lozano, Y., Wright, M.A., Djordjevic, A., Maier,
    G.D. Protein phosphatases-1 and -2A regulate tumor cell migration,
    invasion, and cytoskeletal organization. Proceedings of the 4th
    International Meeting on Eicosanoids and Other Bioactive Lipids in
    Cancer, Inflammation and Radiation Injury, 1995.

37. Roitman-Johnson, B., Sothern, R.B., Kanabrocki, E.L., Yager, J.G.,
    Fuerstenmerg, R.K., Weatherbee, J.A., **Young**, M.R.I., Nemchausky,
    B.M., Shceving, L.E. Comparison of circadian characteristics of
    interleukin-6 in blood and urine in human blood and urine. J.
    Allergy Clin. Immunol., 95:365, 1995.

38. Sothern, R.B., Roitman-Johnson, B., Kanabrocki, E.L., Yager, J.G.,
    Fuerstenmerg, R.K., Weatherbee, J.A., **Young**, M.R.I., Nemchausky,
    B.M., Shceving, L.E. Temporal & functional relationship between
    interleukin-6, leukocytes and serum cortisol in men. J. Allergy
    Clin. Immunol., 95:375, 1995.

39. Lozano, Y., Maier, G.D., Vellody, K., Meisinger, J., **Young**
    M.R.I. Protein kinase A regulates tumor adherence to extracellular
    matrix components and metastasis. Am. Assoc. Cancer Res., Washington
    D.C., 1996.

40. **Young**, M.R.I., Wright, M.A., Lozano, Y., Malik, I., Prechel,
    M.M. Suppression of T-cells by tumor-induced granulocyte-macrophage
    progenitor cells. The FASEB J., 10: A1471, 1996.

41. Pandit, R., Wright, M., **Young**, M.R. Immunosuppressive CD34^+^
    cells in the peripheral blood of head and neck cancer patients.
    Abstract #809, Am. Assoc. Cancer Res., San Diego, CA, 1997.

42. Donzelli, J., Leonetti, J.P., Bergstom, B.S., Wurster, R.D.,
    **Young**, M.R.I. Thermoprotective mechanisms of irrigation during
    bipolar cautery. 101^st^ Meeting of the Am. Acad. Otolaryngology,
    San Francisco, Sept. 8, 1997.

43. Pandit, R., Wright, M.A., Garrity, T., **Young**, M.R.I. CD34^+^
    immune suppressor cells in the blood of head and neck cancer
    patients. 101^st^ Meeting of the Am. Acad. Otolaryngology, San
    Francisco, Sept. 8, 1997.

44. Taitz, A., Benefield, J., Metz, R., Shankar, R., **Young**, M.R.I.
    Chemoattraction of squamous cell carcinomas to endothelial cells.
    101^st^ Meeting of the Am. Acad. Otolaryngology, San Francisco,
    Sept. 9, 1997.

45. Jackson, J.L., Meisinger, J.A., **Young**, M.R.I. Protein
    phosphatase 2A associates with microtubules and controls cellular
    adherence and motility in Lewis lung carcinoma tumor variants. Am.
    Assoc. Cancer Res., New Orleans, LA, 1998.

46. Messingham, K.N., Emami, B., **Young**, M.R.I. Local radiotherapy
    results in systemic monocyte activation in cancer patients. Am.
    Assoc. Cancer Res., New Orleans, LA, 1998.

47. Wy, C.A., Goto, M., **Young**, R., Myers, T.F. Prophylactic
    treatment of endotoxic shock with monophosphoryl lipid A in newborn
    rats. American Pediatric Soc./ Soc. Pediatric Res., 1999.

48. Lathers, D.R., Wright, M.A., **Young**, M.R.I. Differentiation of
    cancer induced CD34^+^ cells. Abstract #248.5, Am. Assoc. Immunol.
    Meeting/Exp. Biol. '99, Washington D.C., 1999.

49. Messingham, K.A., **Young**, M.R.I. Macrophage function and response
    to gamma-radiation. Am. Assoc. Immunol. Meeting/Exp. Biol. '99,
    Washington D.C., 1999.

50. Gabel, S., Benefield, J., Mesinger, J., Petruzzelli, G.J.,
    **Young**, M.R.I. Protein phosphatases‑1 and --2A maintain
    endothelial cells in a resting state, limiting the motility that is
    needed for the morphogenic process of angiogenesis. 1999 Annual
    Meeting, Am. Acad. Otolaryngol. - Head and Neck Cancer, New Orleans,
    1999.

51. **Young**, M.R.I., Beal, N., Lingen, N.W., Gabrilovich, D.I.
    Contribution of vasculogenesis to tumor vascularization. Abstract
    #556, Am. Assoc. Cancer Res., San Francisco, CA, 2000.

52. Lathers, D.M.R., Beal, N.M., Clark, J., **Young**, M.R.I. Treatment
    of cancer patients with 25-hydroxyvitamin D~3~ to improve immune
    function. Am. Assoc. Immunol. Meeting, Seattle, WA, 2000.

53. **Young**, M.R.I., Lingen, M.W., Gabrilovich, D.I. Contribution of
    CD34^+^ progenitor cells to tumor vascularization. Abstract \#
    PA356. 5^th^ Int. Conf. Head and Neck Cancer, San Francisco, CA,
    2000.

54. Shafer, L.L., **Young**, M.R.I., McNulty, J. IL-10 mimics the
    differential response of brain cocultures on activation of a
    microglial cell line. 30^th^ Annual Meeting, Soc. Neurosci., New
    Orleans, LA, 2000.

```{=html}
<!-- -->
```
55. **Young**, M.R.I., Lathers, D.M.R., Achille, N., Kolesiak, K.,
    Petruzzelli, J.G. Immunotherapy for head and neck cancers based on
    the conversion of tumor-mobilized immune inhibitory progenitor cells
    into antigen-presenting dendritic cells. Abstract #516, 11^th^
    International Congress for Immunology, Stockholm, 2001.

56. Wachter, B.G., Leonetti, J.P., Lee, J.M., Wurster, R.D., **Young**,
    M.R.I. Silver nitrate injury in the rat sciatic nerve: A model of
    facial nerve injury. 2001 Annual Meeting, Am. Acad. Otolaryngol. -
    Head and Neck Cancer, Denver, 2001.

```{=html}
<!-- -->
```
55. Kolesiak, K., Achille, N., Lathers, D.M.R., Gabrilovich, D.,
    Petruzzelli G.J., **Young**, M.R.I. Head and neck squamous cell
    carcinomas chemoattract immune suppressive CD34^+^ cells. Lung
    Cancer, 34: \$55, 2001.

56. Kanabrocki, E.L., Ryan, M.D., Hermida, R.C., Ayala, D.E., Lathers,
    D., Achille, N., **Young**, M.R.I., Bremner, W.F., Third, J.L.H.C.,
    Shirazi, P., Siegel, G., Nemchausky, B.A., Hooper, D.C. Disconnected
    variables in blood and urine in multiple sclerosis patients.
    Chronobiol. Int., 18:1136-1137, 2001.

57. Lathers, D.M.R., Clark, J.J., Achille, N.J., **Young**, M.R.I. Phase
    1B trial treating cancer patients with 25-hydroxyvitamin D~3~ to
    improve immune function. Lung Cancer, 34: \$55, 2001.

58. Lathers, D.M.R., Clark, J.J., Achille, N.J., **Young**, M.R.I. Phase
    1B trial treating cancer patients with 25-hydroxyvitamin D~3~ to
    improve immune function. Am. Assoc. Immunol. Meeting/Exp. Biol. '02,
    Abstract LB485, New Orleans, 2002.

59. **Young**, M.R.I., Kolesiak, K., Meisinger, J., Liu, S. Crossover
    between serine phosphatase and tyrosine kinase pathways that
    regulate angiogenesis. Abstract \# 121, Am. Head Neck Soc., Abstract
    278, McLean VA, 2002.

60. Lathers, D.M.R., Achille, N.J., Bier-Laning, C., Petruzzelli, G.J.,
    **Young**, M.R.I. Plasma levels of immune modulating cytokines in
    head and neck squamous cell carcinoma patients. Abstract #040, Am.
    Head Neck Soc., Abstract 278, McLean VA, 2002.

61. Bier-Laning, C.M., Schroeder, M., **Young**, M.R.I. Cellular
    invasion differences are associated with differences in FAK and Src
    in normal keratinocytes versus malignant squamous cells. Abstract
    #074, Am. Head Neck Soc., Abstract 278, McLean VA, 2002.

62. Lathers, D.M.R., Clark, J.I., Achille, N.J., **Young**, M.R.I. Phase
    1B trial treating head and neck cancer patients with
    25-hydroxyvitamin D3 to improve immune function. Abstract \# 0142,
    Am. Head Neck Soc., Abstract 278, McLean VA, 2002.

63. Lathers, D.M.R., Achille, N.J., **Young**, M.R.I. Plasma levels of
    immune modulating cytokines in head and neck squamous cell carcimona
    patients. Abstract #1702, Am. Assoc. Immunol., Denver, CO, 2003.

64. Young, M.R.I. Prevention and treatment of head and neck cancer: from
    laboratory to clinic. Invited talk for the Charleston Swallowing
    Conference, January 31, 2004.

65. **Young**, M.R.I. Tumor blood vessel development by vasculogenesis,
    not only angiogenesis. Am. Assoc. Immunol. Meeting/Exp. Biol. '04,
    Abstract 2663, Washington D.C., April 21, 2004.

66. Block, M.I., Blanton, M.G., Lathers, D.M.R., **Young**, M.R.I. STAT4
    and STAT6 regulate naïve CD8 cell type 1 but not type 2 cytokine
    production. 12^th^ Int. Congress of Immunol., Montreal, Canada,
    2004.

67. **Young**, M.R. CD34^+^ cells of cancer patients - from immune
    suppression to tumor vascularization. Grand Rounds, Department of
    Medicine, Medical University of South Carolina. July 27, 2004.

68. Lathers, D.M.R., Stilley, M., **Young**, M.R.I. Analyses of squamous
    cell carcinoma-recruited T-cell subpopulations. 6^th^ International
    Conference on Head and Neck Cancer, Abstract #p1-030, Washington
    D.C., 2004.

69. **Young**, M.R.I. Tumor blood vessel development by vasculogenesis,
    not only angiogenesis. 6^th^ International Conference on Head and
    Neck Cancer, Abstract #p1-013, Washington D.C., 2004.

70. **Young**, M.R. Combination docetaxel plus vitamin D~3~ as an immune
    therapy in animals bearing SCC squamous cell carcinomas. Am. Assoc.
    Immunol. Meeting/Exp. Biol. '05, Abstract 11561, San Diego, CA,
    April 5, 2005.

71. Woodworth, B.A., Lathers, D.M.R., Skinner, M., Neal. J.G.,
    **Young**, M.R.I., Schlosser, R.J. Immunolocalization of surfactant
    protein A and D in sinonasal mucosa. Los Angeles, CA, American
    Rhinological Society, accepted for oral presentation, 2005.

72. **Young**, M.R.I., Lathers, D., Neville, B., Day, T., Gillespie,
    M.B. Feasibility of using premalignant oral lesions as a source of
    tumor antigen to stimulate immune reactivity against head and neck
    cancer. American Association of Immunologists Meeting, Boston, May
    15, 2006.

73. **Young**, M.R.I., Day, T.A., Gillespie, M.B., Lathers, M.R.I.
    Mechanisms by which oral squamous cell carcinomas stimulate
    endothelial cell motility to facilitate vascularization. American
    Association for Cancer Research's Advances and Challenges in
    Aerodigestive Epithelial Cancer conference. February 7, 2007.

74. Mulligan, J.K., Lathers, D.M.R., **Young**, M.R. Tumor-secreted
    VEGF‑A disrupts endothelial cell stimulation of T‑cell, macrophage
    and NK functions. American Association of Immunologists Meeting,
    Miami Beach, May 20, 2007.

75. Mailloux^,^ A.W., Lathers, D.M.R., **Young**, M.R.I. Lewis lung
    carcinoma-derived CCL22 recruitment of T regulatory cells. American
    Association of Immunologists Meeting, Miami Beach, May 22, 2007.

76. Lathers, D.M.R., Kearney^,^ P.L., Gibbs^,^ K., **Young**, M.R.I.
    Tumor modulation of T-helper cytokine secretion. American
    Association of Immunologists Meeting, Miami Beach, May 20, 2007.

77. Walsh, J.E., **Young**, M.R.I. TGF-β induces microvascular
    endothelial cell migration and PP-2A inactivation. American
    Association of Immunologists Meeting, Miami Beach, May 22, 2007.

78. Mailloux, A.W., Lathers, D.M.R., **Young**, M.R.I. Lewis Lung
    Carcinoma (LLC) alters the phenotype of murine lung mast cells
    resulting in a phenotype consistent with myeloid-derived suppressor
    cells (MDSCs). Abstract \# 5095 (poster and oral presentations),
    American Association of Immunologists Annual Meeting, Experimental
    Biology 2008, San Diego, April 6, 2008.

79. Mailloux, A.W., **Young**, M.R.I. Myeloid-derived suppressor cells
    and tumor-associated macrophages produce CCL22 which selectively
    recruits regulatory T‑cells to the tumor microenvironment. American
    Association of Immunologists Meeting, San Diego, April 6, 2008.

80. Mulligan, J.K., Day, T.A., Gillespie, M.B., Rosenzweig, S.A.,
    **Young**, M.R.I. . Novel use of VEGF & Cox-1/Cox-2 targeting
    therapies in blocking HNSCC- induction of immune suppressive
    endothelial cells.  American Association of Immunology Meeting, Sand
    Diego, April 6, 2008..

81. Walsh, J.E., **Young**, M.R.I. Phosphatase regulation of cellular
    motility in the tumor microenvironment.   American Association of
    Immunology Meeting, Sand Diego, April 6, 2008.